



(51) International Patent Classification:

A61K 39/245 (2006.01) A61P 35/00 (2006.01)
A61P 17/00 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2020/012170

(22) International Filing Date:

03 January 2020 (03.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16/238,933 03 January 2019 (03.01.2019) US

(71) Applicant: **ALBERT EINSTEIN COLLEGE OF MEDICINE** [US/US]; 1300 Morris Park Avenue, Bronx, New York 10461 (US).

(72) Inventor: **HEROLD, Betsy**; 12 Pine Point Road, Rowayton, Connecticut 06853 (US).

(74) Agent: **WARREN STEWART, Lynn M.**; CANTOR COLBURN LLP, 20 Church St., 22nd Floor, Hartford, Connecticut 06103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PASSIVE TRANSFER OF IMMUNITY USING RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS




Fig. 2 C

(57) Abstract: Methods for passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such.

WO 2020/142677 A1

PASSIVE TRANSFER OF IMMUNITY USING RECOMBINANT HERPES SIMPLEX
VIRUS 2 (HSV-2) VACCINE VECTORS

CROSS-REFERENCE TO RELATED APPLICATIONS

This PCT International application claims priority to U.S. Serial No. 15/995,471, filed January 3, 2019, which is a continuation-in-part of U.S. Serial No. 15/995,471 filed on June 1, 2018, which is a continuation of U.S. Patent Application No. 15/015,322, filed February 4, 2016, now U.S. Patent No. 9,999,665, issued June 19, 2018, which is a continuation-in-part of PCT International Application PCT/US2015/018272, filed March 2, 2015, which claims benefit of U.S. Provisional Application No. 61/946,965, filed March 3, 2014, and of U.S. Provisional Application No. 62/080,663, filed November 17, 2014, the contents of all of which are hereby incorporated by reference.

STATEMENT OF GOVERNMENT SUPPORT

[0001] This invention was made with government support under grant numbers AI061679, AI51519, AI097548, AI026170 and AI065309 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

[0002] Throughout this application various publications are referred to, including by number in square brackets. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

[0003] Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) persist as significant health problems globally, disproportionately impacting developing countries and poor communities around the world and fueling the HIV epidemic. Vaccines are urgently needed for these infections as currently there is no effective vaccine for HSV-1, HSV-2 or HIV. HSV-1 is the primary cause of infectious blindness, while HSV-2 is the primary cause of genital ulcers globally, although HSV-1 is now more commonly identified in association with genital tract disease in developed countries. Genital herpes is a recurrent, lifelong disease that can stigmatize and psychologically impacts those affected. Infection with HSV-

2 significantly increases the likelihood of acquiring and transmitting HIV, while vertical transmission of either serotype often leads to severe infant morbidity or death. Recent clinical trials of HSV-2 vaccines based on sub-unit formulations using viral glycoproteins D alone or in combination with glycoprotein B (gD and gB) have failed, despite inducing systemic neutralizing antibodies. Surprisingly an HSV-2 gD subunit (gD-2) vaccine provided partial protection against HSV-1, but no protection against HSV-2. Several attenuated viruses been evaluated pre-clinically, but clinical studies to date have been limited to therapeutic applications (reducing frequency of recurrences) and have also failed to show efficacy. Thus, novel vaccine strategies must be engineered and evaluated.

[0004] The present invention addresses this need for new and improved HSV-1 and HSV-2 vaccines.

SUMMARY OF THE INVENTION

[0005] A method is provided of eliciting an immune response in a first subject against an HSV-2 and/or HSV-1 infection, comprising effectuating passive transfer to the first subject of an amount of a product from a pregnant female immunized with HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, wherein the product comprises antibodies induced thereby, effective to elicit an immune response against an HSV-2 and/or HSV-1 infection in the first subject, wherein the first subject is a fetus or neonate.

[0006] A method is provided of inhibiting a perinatal HSV-1 and/or HSV-2 infection in a neonate comprising administering to a female pregnant with a fetus which will become the neonate an amount of an HSV-1 and/or HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, effective to inhibit a perinatal HSV-1 and/or HSV-2 infection in a neonate.

[0007] A method is provided in inhibiting HSV-1 and/or HSV-2 viral dissemination from a mother to her neonate comprising administering to the mother an amount of an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex

virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, effective to inhibit HSV-1 and/or HSV-2 viral dissemination from a mother to her neonate.

[0008] An isolated, recombinant herpes simplex virus-2 (HSV-2) is provided having a deletion of an HSV-2 glycoprotein D-encoding gene (*Us6*) in the genome thereof.

[0009] Also provided is a virion of an isolated, recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene (*Us6*) in the genome thereof.

[0010] An isolated cell is provided comprising therein a recombinant HSV-2 genome as described herein or a recombinant HSV-1 gene as described herein, wherein the cell is not present in a human being.

[0011] Also provided is a vaccine composition comprising the recombinant HSV-2 virus as described herein, or the virion as described herein.

[0012] Also provided is a composition comprising the recombinant HSV-2 virus as described herein, or the virion as described herein, wherein the genome of the virus or virion comprises at least a deletion of a second gene, wherein the second gene is necessary for HSV-2 viral replication or virulence.

[0013] A pharmaceutical composition comprising the recombinant HSV-2 virus as described herein, or the virion as described herein, and a pharmaceutically acceptable carrier.

[0014] Also provided is a method of eliciting an immune response in a subject comprising administering to the subject an amount of (i) the recombinant HSV-2 virus as described herein; (ii) a virion thereof as described herein, (iii) the vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to elicit an immune response in a subject.

[0015] Also provided is a method of treating an HSV-1, HSV-2 or HSV-1 and HSV-2 co-infection in a subject or treating a disease caused by an HSV-1, HSV-2 or co-infection in a subject comprising administering to the subject an amount of (i) the recombinant HSV-2 virus as described herein; (ii) a virion thereof as described herein, (iii) the vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to treat an HSV-1, HSV-2 or co-infection or treat a disease caused by an HSV-1, HSV-2 or co-infection in a subject.

[0016] Also provided is a method of vaccinating a subject for HSV-1, HSV-2 or co-infection comprising administering to the subject an amount of (i) the recombinant HSV-2

virus as described herein; (ii) a virion thereof as described herein, (iii) the vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to vaccinate a subject for HSV-1, HSV-2 or co-infection.

[0017] Also provided is a method of immunizing a subject against HSV-1, HSV-2 or co-infection comprising administering to the subject an amount of (i) the recombinant HSV-2 virus as described herein; (ii) a virion thereof as described herein, (iii) the vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to immunize a subject against HSV-1, HSV-2 or co-infection.

[0018] In an embodiment of the vaccines, compositions and pharmaceutical compositions, and of the methods of use thereof, the amount of recombinant HSV-2 is an amount of pfu of recombinant HSV-2 effective to achieve the stated aim.

[0019] Also provided is a method of producing a virion of a recombinant herpes simplex virus-2 (HSV-2), having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof and comprising a HSV-1 or HSV-2 glycoprotein D on a lipid bilayer thereof, comprising infecting a cell comprising a heterologous nucleic acid encoding a HSV-1 or HSV-2 glycoprotein D with a recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof under conditions permitting replication of the recombinant herpes simplex virus-2 (HSV-2) and recovering a HSV-2 virion produced by the cells.

[0020] Also provided is a recombinant nucleic acid having the same sequence as a genome of a wild-type HSV-2 except that the recombinant nucleic acid does not comprise a sequence encoding an HSV-2 glycoprotein D.

[0021] Also provided is an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-1, HSV-2 or co-infection in a subject.

[0022] Also provided is a virion of an isolated, recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-1, HSV-2 or co-infection in a subject.

[0023] An isolated, recombinant herpes simplex virus-2 (HSV-2) is provided having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof.

[0024] Also provided is a virion of an isolated, recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof.

[0025] Also provided is an isolated cell comprising therein a virus as described herein or a virion as described herein, wherein the cell is not present in a human being.

[0026] A vaccine composition comprising a virus as described herein, or a virion as described herein.

[0027] Also provided is a composition comprising a virus as described herein, or a virion as described herein, wherein the genome of the virus or virion comprises at least a deletion of a second gene, wherein the second gene is necessary for HSV-2 viral replication.

[0028] Also provided is pharmaceutical composition comprising a virus as described herein, or a virion as described herein, and a pharmaceutically acceptable carrier.

[0029] Also provided is a method of eliciting an immune response in a subject comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to elicit an immune response in a subject.

[0030] Also provided is a method of treating an HSV-2 infection in a subject or treating a disease caused by an HSV-2 infection in a subject comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to treat an HSV-2 infection or treat a disease caused by an HSV-2 infection in a subject.

[0031] Also provided is a method of vaccinating a subject for HSV-2 infection comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to vaccinate a subject for HSV-2.

[0032] Also provided is a method of immunizing a subject against HSV-2 infection comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to immunize a subject against HSV-2.

[0033] Also provided is a method of producing a virion of a recombinant herpes simplex virus-2 (HSV-2), having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof and comprising an HSV-1 glycoprotein D on a lipid bilayer thereof, comprising infecting a cell comprising a heterologous nucleic acid encoding a HSV-1 glycoprotein D with a recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof under conditions permitting replication of the recombinant herpes simplex virus-2 (HSV-2) and recovering a recombinant HSV-2 virion comprising an HSV-1 glycoprotein D on a lipid bilayer thereof produced by the cell.

[0034] Also provided is a method of producing a virion of a recombinant herpes simplex virus-2 (HSV-2), having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof and comprising a non-HSV-2 surface glycoprotein on a lipid bilayer thereof, comprising infecting a cell comprising a heterologous nucleic acid encoding the non-HSV-2 surface glycoprotein with a recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof under conditions permitting replication of the recombinant herpes simplex virus-2 (HSV-2) and recovering a recombinant HSV-2 virion comprising a non-HSV-2 surface glycoprotein on a lipid bilayer thereof produced by the cell.

[0035] Also provided is a recombinant nucleic acid is provided having the same sequence as a genome of a HSV-2 except that the sequence does not comprise a sequence encoding an HSV-2 glycoprotein D.

[0036] Also provided is an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-2 infection in a subject.

[0037] Also provided is an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-1 infection in a subject.

[0038] Also provided is a virion of an isolated, recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-2 infection in a subject.

[0039] Also provided is a method of treating an HSV-1 infection, or HSV-1 and HSV-2 co-infection, in a subject, or treating a disease caused by an HSV-2 infection or HSV-1 and HSV-2 co-infection in a subject comprising administering to the subject an amount of (i) a

virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to treat an HSV-2 infection or treat a disease caused by an HSV-2 infection in a subject or an amount effective to treat an HSV-1 and HSV-2 co-infection or treat a disease caused by an HSV-1 and HSV-2 co-infection in a subject.

[0040] Also provided is a method of vaccinating a subject for an HSV-1 infection, or HSV-1 and HSV-2 co-infection, comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to vaccinate a subject for an HSV-1 infection, or HSV-1 and HSV-2 co-infection.

[0041] Also provided is a method of immunizing a subject against an HSV-1 infection, or HSV-1 and HSV-2 co-infection, comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to immunize a subject against an HSV-1 infection, or HSV-1 and HSV-2 co-infection.

[0042] Also provided is an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof and further comprising a heterogenous antigen of a pathogen.

[0043] Also provided is a method of inducing antibody dependent cell mediated cytotoxicity (ADCC) against an antigenic target in a subject comprising administering to the subject an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof and further comprising a heterogenous antigen on a lipid bilayer thereof in an amount effective to induce antibody dependent cell mediated cytotoxicity (ADCC) against an antigenic target.

BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Fig. 1: HSV-2 Δ gD initiates an abortive infection: HSV-2 Δ gD/+ only replicates successfully in cells that provide gD in *trans* (e.g. VD60 [40, 41]), but not in cells such as Vero cells (ATCC CCL-81, Green monkey kidney) or CaSki (ATCC CRL-1550, Homo

sapiens, cervix) that do not encode *Us6*. Non-complemented HSV-2 Δ gD (Δ gD^{-/-} obtained from Vero cells) cannot infect cells such as Vero and CaSki, which do not encode *Us6*.

[0045] Fig. 2A-C: A. Severe combined immunodeficiency (SCID) mice inoculated with up to 10^7 plaque-forming units (pfu) of HSV-2 Δ gD^{-/+} virus do not manifest signs of disease after high dose intravaginal or subcutaneous inoculation. In contrast SCID mice inoculated with wild-type virus at a 1,000-fold lower viral dose (10^4 pfu) succumb to disease. Survival curves are shown in A, epithelial scores (scale of 0 to 5) for evidence of erythema, edema, or genital ulcers in B and neurological scores (scale of 0 to 5) for evidence of neuronal infection in C.

[0046] Fig. 3A-C: Immunization with HSV-2 Δ gD^{-/+} virus elicits anti-HSV-2 antibodies. While sc.-sc. immunization elicits significant levels of both systemic and mucosal (vaginal washes) anti-HSV-2 antibodies, sc.-i.vag. immunization with HSV-2 Δ gD^{-/+} elicits lower levels of systemic anti-HSV-2 antibodies and no increase in antibody levels in vaginal washes. Anti-HSV-2 antibody levels in serum are shown in A and anti-HSV-2 antibody levels in vaginal washes are shown in B. Mice immunized with Δ gD^{-/+} display neutralizing anti-HSV-2 antibodies in the serum after challenge with virulent HSV-2. The neutralizing capacity of the antibodies elicited by Δ gD^{-/+} immunization is shown in C. (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$).

[0047] Fig. 4A-C: A: CD8⁺ gBT-I T cell counts in spleens of C57Bl/6 mice transferred with Tg T cells, then primed and boosted with HSV-2 Δ gD^{-/+} or VD60 lysate (Control). B: Percentage of gBT-I memory T cells in spleens of vaccinated or Control mice. C: 14 days after boost, splenocytes were isolated and re-stimulated *in vitro* with gB498-505 peptide and analyzed 6 hr later for cytokine production by intracellular cytokine staining and flow cytometry. (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$).

[0048] Fig. 5A-F: Immunization with HSV-2 Δ gD^{-/+} (10^6 pfu/mouse) protects mice from a lethal HSV-2 challenge. Mice were primed subcutaneously and boosted 3-weeks apart either sc. or i.vag. and then challenged 3-weeks after boost intravaginally with an LD₉₀ of virulent wild-type HSV-2(4674). While Control (immunized with the VD60 cell lysate) mice succumbed to disease, as manifested by significant weight loss (5A) and death (5B), Δ gD^{-/+}-immunized mice displayed significantly less pathology. Furthermore, Δ gD^{-/+}-immunized mice showed less epithelial disease (C) and neurological pathology (D) after lethal challenge. Additionally, Δ gD^{-/+}-vaccinated mice displayed significantly less viral loads in vaginal washes (E), vaginal tissue and dorsal root ganglia (DRG) (F) after

intravaginal challenge with a lethal dose of virulent HSV-2 compared to mice immunized with VD60 cell lysate as a Control. No infectious virus could be recovered from Δ gD-/+ immunized mice in Day 4 vaginal washes or Day 5 vaginal tissue and DRG. (*p<0.05; **p<0.01; ***p<0.001).

[0049] Fig. 6A-C: Mice immunized with HSV-2 Δ gD-/+ secrete less inflammatory cytokines in vaginal washes after challenge with virulent HSV-2. Mice immunized with HSV-2 Δ gD-/+ secrete less TNF- α , IL-6 and IL-1 β in vaginal washes than mice immunized with VD60 lysate and challenged with virulent HSV-2. Differences in inflammatory cytokine expression are observed at different time-points after challenge. (*p<0.05; **p<0.01; ***p<0.001).

[0050] Fig. 7A-D: Immunization with HSV-2 Δ gD-/+ recruits T cells to the infection site and associated LNs. Mice immunized sc.-sc. with Δ gD-/+ displayed increased percentages of activated anti-HSV-2 gBT-I CD8+ (A) and CD4+ T cells (B) in sacral lymph nodes (LNs) after challenge with virulent HSV-2. LNs were extracted and incubated 6 h with UV-inactivated Δ gD-/- and then stained with antibodies for flow cytometry analysis. Mice immunized sc.-i.vag. with Δ gD-/+ displayed increased numbers of anti-HSV-2 gBT-I CD8+ (C) and CD4+ T cells (D) in the vagina after challenge with virulent HSV-2. Vaginal tissues were processed to extract T cells and stained with antibodies for flow cytometry analysis. Cell counting was done with (CountBright™, Life Technologies). (*p<0.05; **p<0.01).

[0051] Fig. 8A-8C. HSV-2 Δ gD-2 provides complete protection against disease following intravaginal or skin challenge with vaccine doses as low as 5×10^4 PFU. C57BL/6 mice were primed and then 21 days later boosted subcutaneously (sc) with either 5×10^4 PFU, 5×10^5 PFU, 5×10^6 PFU of HSV-2 Δ gD-2 or VD60 lysates (control). Mice were subsequently challenged 21 days after boost with an LD90 of HSV-2(4674) either (A) intravaginally or (B) via skin scarification and followed for survival (n=5 mice/group) and disease scores (C). Serum was assessed for HSV-2 antibodies before (PreBleed), day 7 post-prime, and day 7 post boost via ELISA (line represents mean). *p<0.05, **p<0.01, ***p<0.001, Δ gD-2 vaccinated groups vs. control-vaccinated group via two-way ANOVA. Kaplan Meier analysis was used for survival curves.

[0052] Fig 9A-9D. Mice vaccinated with HSV-2 Δ gD-2 are protected against clinical isolates of HSV-1 and HSV-2. C57BL/6 (n=7 mice/group) or Balb/C (n=5 mice/group) mice were immunized with Δ gD-2 or VD60 cell lysates (Control) and subsequently

challenged with an LD90 dose of most virulent isolates and monitored daily for lesions in the skin (9A; representative images from C57BL/6 mice), survival (9B; C57BL/6 mice and 9C; Balb/C). Additional C57BL/6 mice were challenged with 10 and 100 times (10x and 100x) the LD90 dose of SD90 and 10x the LD90 of Bx³1.1 and monitored for survival (9D). Survival for HSV-2 Δ gD-2-vaccinated group vs. control-vaccinated group were compared by Kaplan Meier analysis, ***p<0.001).

[0053] Fig. 10A-10D. Virus is rapidly cleared and no latent virus is detected in HSV-2 Δ gD-2 immunized mice following challenge with clinical isolates. Mice were immunized with Δ gD-2 or VD60 cell lysates (Control) and subsequently challenged by skin scarification with a 1x or 10x the LD90 of HSV-1(B³x1.1) or with 1x, 10x or 100x the LD90 of HSV-2 (SD90) (n=5 mice per group). Skin biopsies were obtained on day 2 and day 5 post-challenge and assayed for viral load by plaque assay on Vero cells (10A) (n=3 samples/group, line represents mean). The presence of replicating or latent HSV in DRG tissue obtained from Δ gD-2 vaccinated (day 14 post challenge) or control vaccinated (time of euthanasia) mice by plaque assay (10B) and qRT-PCR (10C), respectively (n=5 mice/group). Latency was further evaluated by co-culturing Vero cells with DRG isolated from Δ gD-2 and control immunized mice that were challenged with an LD90 of HSV-2 SD90 at day 5 post-challenge (10D). Data in Panels B and C are presented as box and whisker plots with black dots indicating outliers. HSV-2 Δ gD-2-vaccinated group and control-vaccinated groups were compared by student's t-test; *p<0.05; **p< 0.01; ***p<0.001.

[0054] Fig 11A-11D. HSV-2 IgG2 specific antibodies are rapidly recruited into the skin of HSV-2 Δ gD-2 vaccinated mice following viral challenge. (11A) Mice were immunized with Δ gD-2 or VD60 cell lysates (Control) and subsequently challenged with HSV-1(B³x1.1) and HSV-2(SD90) clinical isolates on the skin. Skin biopsies were obtained 21 days post-boost and day 2 post-challenge and evaluated for the presence of anti-HSV antibodies in homogenates (1:10³ dilution) by ELISA using an HSV-2 (left) or HSV-1 (right) infected cell lysate as the antigen (n=3 mice per group, line represents mean). To further quantify the HSV-specific antibodies in the skin, pools of skin homogenates were serially diluted and assayed in the HSV-2 ELISA (6 mice per pool and results are mean \pm SD obtained from duplicates) (11B). The ratio of anti-HSV-2 IgG sub-isotypes in the day 2 post-challenge skin homogenate pool was determined using sub-isotype specific secondary antibodies (11C). Antibody-dependent-cellular-phagocytosis (ADCP) activity

(left panel) of serum from HSV-2 Δ gD-2 or control vaccinated mice 7 days post-boost was quantified using THP-1 monocytic cell line and beads coated with HSV-2 viral cellular lysates (v) or cellular lysates (c). IFN- γ levels (right panel) were measured in the supernatants 8 hr post THP-1 and Ab/bead incubation (11D). The %ADCP is calculated as percent of cells positive for beads multiplied by the MFI of positive cells divided by 10^6 (left panel). (* p <0.05; ** p < 0.01; *** p <0.001, HSV-2 Δ gD-2 vs. control-vaccinated group, student's t-test)

[0055] Fig 12A-12H. Adaptive and innate immune cells are recruited to infected skin by day 5 post-challenge in HSV-2 Δ gD-2 vaccinated mice. Skin sections from mice immunized with Δ gD-2 or VD60 lysates (control) and then challenged with LD90 of SD90 or Bx³1.1 or unvaccinated mock-infected controls were stained for CD3⁺ (T cells) (12A), B220⁺ (B cells) (12B) or Iba1⁺ (pan macrophage) (12C); representative immunohistochemistry images following challenge with HSV-1(B³x1.1) or HSV-2(SD90) are shown. The percentage of CD3⁺ (12D), B220⁺ (12E), and Iba1⁺ (12F) cells were enumerated by counting 3 random fields per mouse (5 mice per group). Skin sections were also stained for CD4⁺ (12G) and CD8⁺ (12H) by immunofluorescence and the percentage positive cells quantified. Each symbol is the average of the 2 fields for individual mouse and the line represents mean; the dashed line represents counts from unvaccinated, mock-infected mice (3 fields averaging for 1 mouse) (* p <0.05, Δ gD-2- vs. control-vaccinated group by student's t-test).

[0056] Fig 13. Control but not Δ gD-2 vaccinated mice have persistent neutrophil infiltration in skin biopsies. Skin sections of unimmunized mock-infected mice or mice immunized with HSV-2 Δ gD-2 or VD60 lysates (control) and infected with HSV-1(B³x1.1) virus were harvested on Day 5 post-challenge and stained for neutrophils using Ly6G (red). Nuclei are stained blue with DAPI.

[0057] Fig. 14A-14F. Mice immunized with Δ gD-2 have decreased inflammatory cytokines and chemokines in the skin compared to control immunized mice by day 5 post-challenge. Biopsies of skin from mice immunized with Δ gD-2 or VD60 lysates (Control) at day 2 or day 5 post-challenge (or unimmunized, uninfected controls) were homogenized and evaluated for TNF (14A), IL-1 β (14B), IL-6 (14C), CXCL9 (14D), CXCL10 (IP-10) (14E), and IL-33 (14F) (n=6 animals/group, line represents mean, dashed line represents counts from unimmunized, mock infected animals). (* p <0.05; ** p < 0.01; *** p <0.001, HSV-2 Δ gD-2-vaccinated group vs. control-vaccinated group students t-test).

[0058] Fig. 15A-15C. Maternal immunization with Δ gD-2 protects neonates; age dependent response. Graphs illustrate percent survival versus days. Significant protection against HSV-1 and HSV-2 was observed in 7 (15A) and 14-day (15B) old pups born to Δ gD-2 vaccinated dams, but protection was reduced when pups were challenged on day 1 of life (15C).

[0059] Fig. 16A-16D. Protection correlates with transfer of HSV-specific Fc γ RIV-Activating Antibodies. 7 day old pups born to either Δ gD-2 or VD60 (control) vaccinated dams were challenged intranasally with 10^5 pfu of HSV-1 or HSV-2, and serum was collected from pups at time of sacrifice or day 14-post challenge and assessed as follows: 16A: HSV-1 (closed symbols) or HSV-2 (open symbols) specific IgG quantified by ELISA at 1:1000 dilution; 16B: IgG subtypes of the HSV-1-specific or HSV-2-specific antibodies demonstrate that Δ gD-2 induces both IgG1 and IgG2 with slightly predominance of IgG2; 16C: Neutralizing antibody titers demonstrate little or no complement-independent neutralization by Δ gD-2 immune serum (1:5 dilution); and 16D: Fc γ RIV-activating antibody titers.

[0060] Fig. 17. Δ gD-2 maternal vaccination reduces amount of HSV viral DNA detected in trigeminal ganglia, the site of latency. Neonatal mice born to vaccinated mothers have reduced log # of copies of HSV based on qPCR in their trigeminal ganglia (which is the site of latency with intranasal infection).

[0061] Fig. 18A-18D. Δ gD-2 maternal vaccination reduced dissemination to vital organs (lung, liver, brain, kidney).

[0062] Fig. 19A-19B. Transplacental and breastmilk acquired Abs provide optimal protection in the murine model. Pups born to Δ gD-2 or VD60 (control) immunized dams were switched at birth and nursed by the opposite dam and then challenged with HSV-1 (19A) or HSV-2 (19B) on Day 7 or Day 14 of life. Pups born to a Δ gD-2 vaccinated mother were significantly protected if nursed by that dam but lost protection if nursed by a VD60-immunized mother. Conversely, pups born to a VD60-immunized mom were also significantly protected from viral challenge on Day 7 or Day 14 if nursed by a Δ gD-2 vaccinated dam.

[0063] Fig. 20. Optimal protection against latency via transplacental and breastmilk acquired Abs.

[0064] Fig. 21A-21B. Protection is correlated with Ab levels present in the neonate's serum at time of challenge.

[0065] Fig. 22A-22D. Convalescent immune serum from mice infected with a sublethal dose of HSV failed to protect pups from subsequent viral challenge.

DETAILED DESCRIPTION OF THE INVENTION

[0066] A method is provided of eliciting an immune response in a first subject against an HSV-2 and/or HSV-1 infection, comprising effectuating passive transfer to the first subject of an amount of a product from a pregnant female immunized with HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, wherein the product comprises antibodies induced thereby, effective to elicit an immune response against an HSV-2 and/or HSV-1 infection in the first subject, wherein the first subject is a fetus or neonate.

[0067] In embodiments, the product comprises serum of the pregnant female.

[0068] In embodiments, the product comprises breast milk of the pregnant female.

[0069] In embodiments, the first subject is a fetus.

[0070] In embodiments, the first subject is a neonate.

[0071] In embodiments, the first subject is born from a second subject.

[0072] In embodiments, the pregnant female is pregnant with the fetus.

[0073] In embodiments, the first subject and the pregnant female are human.

[0074] In embodiments, the product comprises antibodies elicited by immunization of the pregnant female with the HSV-2 having the deletion. In embodiments, the product comprises FcγRIV-activating antibodies. In embodiments, the product comprises IgG1 and IgG2 antibodies. In embodiments, the product comprises anti-HSV-1 IgG or anti-HSV-2 IgG.

[0075] In embodiments, the method elicits an immune response in the first subject against an HSV-2.

[0076] In embodiments, the method elicits an immune response in the first subject against an HSV-1.

[0077] In embodiments, the product further comprises an immunological adjuvant.

[0078] In embodiments, the product further comprises an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D.

[0079] A method is provided of inhibiting a perinatal HSV-1 and/or HSV-2 infection in a neonate comprising administering to a female pregnant with a fetus which will become the neonate an amount of an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, effective to inhibit a perinatal HSV-1 and/or HSV-2 infection in a neonate.

[0080] A method is provided of inhibiting HSV-1 and/or HSV-2 viral dissemination from a mother to her neonate comprising administering to the mother an amount of an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D, effective to inhibit HSV-1 and/or HSV-2 viral dissemination from a mother to her neonate.

[0081] In embodiments, the mother is pregnant with a fetus which will become the neonate.

[0082] In embodiments, the HSV-1 infection and/or HSV-1 viral dissemination is inhibited.

[0083] In embodiments, the HSV-2 infection and/or HSV-2 viral dissemination is inhibited.

[0084] In embodiments, an immune response is elicited against HSV-1.

[0085] In embodiments, an immune response is elicited against HSV-2.

[0086] In embodiments, the complementing cell is a VD60 cell.

[0087] In embodiments, the pregnant female, the mother or the second subject is seronegative for HSV-1, seronegative for HSV-2, or seronegative for both HSV-1 and HSV-2.

[0088] In embodiments, the pregnant female or the mother is subcutaneously administered the HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof.

[0089] In embodiments, the pregnant female or the mother is administered a subcutaneous boost does of the HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof after an initial subcutaneous administration of the HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene.

[0090] An isolated, recombinant herpes simplex virus-2 (HSV-2) is provided having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof.

[0091] In an embodiment, the HSV-2 glycoprotein D comprises the amino acid sequence set forth in SEQ ID NO:1:

MGRLTSGVGTAAALLVVAVGLRVVCAKYALADPSLKMADPNRFRGKNLPVLDQLT
DPPGVKR VYHIQPSLEDPFQPPSIPITVYYAVLERACRSVLLHAPSEAPQIVRGASDE
ARKHTYNLTIAWYRMGDNCAIPITVMEYTECPYNKSLGVCPIRTQPRWSYYDSFSA
VSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRARASCKYALPLRIPPA
ACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYSLKIAGWHGPKPPYTSTLLPEL
SDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPNWHIPSIQDVAPHHAPAAPSNPG
LIIGALAGSTLAVLVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPPSHQPLFY (HSV-
2 reference strain HG52)

[0092] In an embodiment, the isolated, recombinant HSV-2 further comprises a herpes simplex virus-1 (HSV-1) glycoprotein D on a lipid bilayer thereof.

[0093] In an embodiment, the HSV-1 glycoprotein D comprises the amino acid sequence set forth in SEQ ID NO:2:

MGGAAARLGAVILFVVIVGLHGVRGKYALADASLKMADPNRFRGKDLVLDQLT
DPPGVRRVYHIQAGLPDPFQPPSLPITVYYAVLERACRSVLLNAPSEAPQIVRGASE
DVRKQPYNLTIAWFRMGGNCAIPITVMEYTECSYNKSLGACPIRTQPRWNYYSFSA
AVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRAKGSCKYALPLRIPP
SACLSPQAYQQGVTVDSIGMLPRFIPENQRTVAVYSLKIAGWHGPKAPYTSTLLPPE
LSETPNATQPELAPEDPEDSALLEDPVGTVAPQIPPNWHIPSIQDAATPYHPPATPNN
MGLIAGAVGGSLLAALVICGIVYWMRRRTQKAPKRIRLPHIREDDQPSSHQPLFY
(HSV-1 reference strain F)

[0094] In an embodiment, the HSV-2 glycoprotein D-encoding gene is an HSV-2 *U_{S6}* gene. (For example, see Dolan et al. *J Virol.* 1998 March; 72(3): 2010–2021. (PMCID: PMC109494) “The Genome Sequence of Herpes Simplex Virus Type 2” for HSV-2 genome and *U_{S6}* gene, hereby incorporated by reference in its entirety).

[0095] In an embodiment, the HSV-2 in which the HSV-2 glycoprotein D-encoding gene is deleted is an HSV-2 having a genome (prior to the deletion) as set forth in one of the following Genbank listed sequences: HSV-2(G) (KU310668), HSV-2(4674) (KU310667), B3x1.1 (KU310657), B3x1.2 (KU310658), B3x1.3 (KU310659), B3x1.4 (KU310660), B3x1.5 (KU310661), B3x2.1 (KU310662), B3x2.2 (KU310663), B3x2.3 (KU310664), B3x2.4 (KU310665), B3x2.5 (KU310666).

[0096] Also provided is a virion of an isolated, recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof.

[0097] In an embodiment, the virion further comprises an HSV-1 glycoprotein D on a lipid bilayer thereof. In an embodiment, the HSV-2 glycoprotein D-encoding gene is an HSV-2 *U_{S6}* gene.

[0098] In an embodiment, the virus further comprises an HSV-1 on a lipid bilayer thereof. In an embodiment, the HSV-2 glycoprotein D-encoding gene is an HSV-2 *U_{S6}* gene.

[0099] An isolated cell is provided comprising therein a recombinant HSV-2 genome which does not comprise an HSV-2 *U_{S6}* gene.

[00100] In an embodiment, the recombinant HSV-2 genome is recombinant by virtue of having had a HSV-2 glycoprotein D gene deleted therefrom.

[00101] In an embodiment, the cell is a complementing cell which provides expressed HSV 1 or 2 glycoprotein not encoded for by the recombinant HSV-2 genome. In an embodiment, the complementing cell comprises a heterologous nucleic acid encoding a HSV-1 glycoprotein D. In an embodiment, the cell expresses HSV-1 glycoprotein D on a membrane thereof. In an embodiment of the cell, the HSV-1 glycoprotein D is encoded by the heterologous nucleic acid, which heterologous nucleic acid is a HSV-1 glycoprotein D gene, or is a nucleic acid having a sequence identical to a HSV-1 glycoprotein D gene.

[00102] Also provided is a vaccine composition comprising the recombinant HSV-2 virus as described herein, or the virion as described herein. In an embodiment, the vaccine comprises an immunological adjuvant. In an embodiment, the vaccine does not comprise an immunological adjuvant. In an embodiment of the vaccine, compositions or pharmaceutical compositions described herein comprising a recombinant HSV-2, the HSV-2 is live.

[00103] Also provided is a composition comprising the recombinant HSV-2 virus as described herein, or the virion as described herein, wherein the genome of the virus or

virion comprises at least a deletion of a second gene, wherein the second gene is necessary for HSV-2 viral replication or virulence.

[00104] A pharmaceutical composition comprising the recombinant HSV-2 virus as described herein, or the virion as described herein, and a pharmaceutically acceptable carrier.

[00105] In an embodiment, the composition or pharmaceutical composition or vaccine is formulated so that it is suitable for subcutaneous administration to a human subject. In an embodiment, the composition or pharmaceutical composition or vaccine is formulated so that it is suitable for intravaginal administration to a human subject. In an embodiment, the composition or pharmaceutical composition or vaccine is formulated so that it is suitable for intra-muscular, intra-nasal, or mucosal administration to a human subject.

[00106] Also provided is a method of eliciting an immune response in a subject comprising administering to the subject an amount of (i) the recombinant HSV-2 virus as described herein; (ii) a virion thereof as described herein, (iii) the vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to elicit an immune response in a subject.

[00107] Also provided is a method of treating an HSV-2 infection in a subject or treating a disease caused by an HSV-1, HSV-2 or co-infection in a subject comprising administering to the subject an amount of (i) the recombinant HSV-2 virus as described herein; (ii) a virion thereof as described herein, (iii) the vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to treat an HSV-1, HSV-2 or co-infection or treat a disease caused by an HSV-1, HSV-2 or co-infection in a subject. In an embodiment, the methods comprise treating an HSV-1 or HSV-2 pathology caused by an HSV-1, HSV-2 or co-infection. In an embodiment of the methods, the disease caused by an HSV-1, HSV-2 or co-infection is a genital ulcer. In an embodiment of the methods, the disease caused by an HSV-1, HSV-2 or co-infection is herpes, oral herpes, herpes whitlow, genital herpes, eczema herpeticum, herpes gladiatorum, HSV keratitis, HSV retinitis, HSV encephalitis or HSV meningitis.

[00108] In an embodiment of the methods herein regarding treating, or vaccinating for, an HSV-1, HSV-2 or co-infection (i.e. infection with both HSV-1 and HSV-2), separate, individual, embodiments of treating an HSV-1 infection, treating an HSV-2 infection, treating a co-infection, vaccinating against an HSV-1 infection, vaccinating against an HSV-2 infection, and vaccinating against a co-infection, are each provided.

[00109] Also provided is a method of vaccinating a subject for HSV-1, HSV-2 or co-infection comprising administering to the subject an amount of (i) the recombinant HSV-2 virus as described herein; (ii) a virion thereof as described herein, (iii) the vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to vaccinate a subject for HSV-1, HSV-2 or co-infection.

[00110] Also provided is a method of immunizing a subject against HSV-1, HSV-2 or co-infection comprising administering to the subject an amount of (i) the recombinant HSV-2 virus as described herein; (ii) a virion thereof as described herein, (iii) the vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to immunize a subject against HSV-1, HSV-2 or co-infection.

[00111] In an embodiment of the methods, the subject is administered a subcutaneous or intravaginal priming dose and is administered a second dose subcutaneously or intravaginally. In an embodiment of the methods, the subject is administered as many subcutaneous or intravaginal priming doses to elicit anti-HSV antibodies and T cells.

[00112] Also provided is a method of producing a virion of a recombinant herpes simplex virus-2 (HSV-2), having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof and comprising an HSV-1 or HSV-2 glycoprotein D on a lipid bilayer thereof, comprising infecting a cell comprising a heterologous nucleic acid encoding a HSV-1 or HSV-2 glycoprotein D with a recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof under conditions permitting replication of the recombinant herpes simplex virus-2 (HSV-2) and recovering a HSV-2 virion produced by the cell.

[00113] In an embodiment, the cell expresses HSV-1 or HSV-2 glycoprotein D on a membrane thereof.

[00114] Also provided is a recombinant nucleic acid having the same sequence as a genome of a wild-type HSV-2 except that the recombinant nucleic acid does not comprise a sequence encoding an HSV-2 glycoprotein D. In an embodiment, the recombinant nucleic acid is a DNA. In an embodiment, the recombinant nucleic acid is an RNA.

[00115] Also provided is an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-1, HSV-2 or co-infection in a subject. In an embodiment, the

isolated, recombinant HSV-2 further comprises a herpes simplex virus-1 (HSV-1) or herpes simplex virus-2 (HSV-2) glycoprotein D on a lipid bilayer thereof. In an embodiment of the isolated, recombinant HSV-2, the HSV-2 glycoprotein D-encoding gene is an HSV-2 *US6* gene.

[00116] Also provided is a virion of an isolated, recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-1, HSV-2 or co-infection in a subject. In an embodiment, the virion further comprises an HSV-1 or HSV-2 glycoprotein D on a lipid bilayer thereof. In an embodiment, the HSV-2 glycoprotein D-encoding gene is an HSV-2 *US6* gene.

[00117] In an embodiment, of the virus or virion as described, the HSV-1, HSV-2 or co-infection causes a genital ulcer.

[00118] An isolated, recombinant herpes simplex virus-2 (HSV-2) is provided having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof.

[00119] In an embodiment, the isolated, recombinant HSV-2 further comprises a surface glycoprotein on a lipid bilayer thereof which is a herpes simplex virus-1 (HSV-1) glycoprotein D. In an embodiment, the isolated, recombinant HSV-2 further comprises a non-HSV-2 viral surface glycoprotein on a lipid bilayer thereof. In an embodiment, the isolated, recombinant HSV-2 further comprises a bacterial surface glycoprotein on a lipid bilayer thereof. In an embodiment, the isolated, recombinant HSV-2 further comprises a parasitic surface glycoprotein on a lipid bilayer thereof, wherein the parasite is a parasite of a mammal.

[00120] In an embodiment, the HSV-2 glycoprotein D-encoding gene is an HSV-2 *US6* gene. In an embodiment, the surface glycoprotein is encoded by a transgene that has been inserted into the genome of the recombinant HSV-2. In an embodiment, the surface glycoprotein is present on a lipid bilayer thereof by way of infecting a cell with a recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene, wherein the cell is or has been transfected to express the surface glycoprotein on a cell membrane thereof, and wherein the recombinant HSV-2 comprising the surface glycoprotein present on a lipid bilayer is produced from the cell. In an embodiment, the viral glycoprotein is from a HIV, an enterovirus, a RSV, an influenza virus, a parainfluenza virus, Pig corona respiratory virus, a rabies virus, a Lassa virus, a bunyavirus, a CMV, or a filovirus. In an embodiment, the glycoprotein is an HIV gp120. In an embodiment, the filovirus is an ebola virus. In an embodiment, the virus is HIV, a *M. tuberculosis*, a *chlamydia*, *Mycobacterium*

ulcerans, *M. marinum*, *M. leprae*, *M. absenscens*, *Neisseria gonorrhoea*, or a Treponeme. In an embodiment, the Treponeme is *Treponeme palidum*.

[00121] Also provided is a virion of an isolated, recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof.

[00122] In an embodiment, the virion of the isolated, recombinant HSV-2 further comprises a surface glycoprotein on a lipid bilayer thereof which is a herpes simplex virus-1 (HSV-1) glycoprotein D. In an embodiment, the virion of the isolated, recombinant HSV-2 further comprises a non-HSV-2 viral surface glycoprotein on a lipid bilayer thereof. In an embodiment, the virion of the isolated, recombinant HSV-2 further comprises a bacterial surface glycoprotein on a lipid bilayer thereof. In an embodiment, the virion of the isolated, recombinant HSV-2 further comprises a parasitic surface glycoprotein on a lipid bilayer thereof, wherein the parasite is a parasite of a mammal. In an embodiment, the HSV-2 glycoprotein D-encoding gene is an HSV-2 *US6* gene. In an embodiment, the surface glycoprotein is encoded by a transgene that has been inserted into the genome of the recombinant HSV-2 of the virion. In an embodiment, the surface glycoprotein is present on a lipid bilayer thereof by way of infecting a cell with a recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene, wherein the cell is or has been transfected to express the surface glycoprotein on a cell membrane thereof, and wherein the recombinant HSV-2 comprising the surface glycoprotein present on a lipid bilayer is produced from the cell. In an embodiment, the virion has been recovered from such. In an embodiment, the viral glycoprotein is from a HIV, an enterovirus, a RSV, an influenza virus, a parainfluenza virus, Pig corona respiratory virus, a rabies virus, a Lassa virus, a bunyavirus, a CMV, or a filovirus. In an embodiment, the glycoprotein is an HIV gp120. In an embodiment, the filovirus is an ebola virus. In an embodiment, the virus is HIV, a *M. tuberculosis*, a *chlamydia*, *Mycobacterium ulcerans*, *M. marinum*, *M. leprae*, *M. absenscens*, *Neisseria gonorrhoea*, or a Treponeme. In an embodiment, the Treponeme is *Treponeme palidum*.

[00123] Also provided is an isolated cell comprising therein a virus as described herein or a virion as described herein, wherein the cell is not present in a human being. In an embodiment of the cell, the cell comprises a heterologous nucleic acid encoding a HSV-1 glycoprotein D. In an embodiment of the cell, the cell expresses HSV-1 glycoprotein D on a membrane thereof.

[00124] In an embodiment of the cell, the HSV-1 glycoprotein D is encoded by the heterologous nucleic acid, which heterologous nucleic acid is a HSV-1 glycoprotein D gene, or is a nucleic acid having a sequence identical to a HSV-1 glycoprotein D gene.

[00125] A vaccine composition comprising a virus as described herein, or a virion as described herein. In an embodiment of the vaccine composition, the vaccine composition comprises an immunological adjuvant.

[00126] Also provided is a composition comprising a virus as described herein, or a virion as described herein, wherein the genome of the virus or virion comprises at least a deletion of a second gene, wherein the second gene is necessary for HSV-2 viral replication. In an embodiment, the composition comprises serum from, or is derived from serum from, a mammal into which the virus or virion has been previously introduced so as to elicit an immune response.

[00127] Also provided is pharmaceutical composition comprising a virus as described herein, or a virion as described herein, and a pharmaceutically acceptable carrier.

[00128] Also provided is a method of eliciting an immune response in a subject comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to elicit an immune response in a subject.

[00129] Also provided is a method of treating an HSV-2 infection in a subject or treating a disease caused by an HSV-2 infection in a subject comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to treat an HSV-2 infection or treat a disease caused by an HSV-2 infection in a subject.

[00130] Also provided is a method of vaccinating a subject for HSV-2 infection comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to vaccinate a subject for HSV-2.

[00131] Also provided is a method of immunizing a subject against HSV-2 infection comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as

described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to immunize a subject against HSV-2.

[00132] HSV-2 and HSV-1 diseases are known in the art, and are also described herein. Both treatment and prevention of HSV-2 and HSV-1 diseases are each separately encompassed. Also treatment or prevention of a HSV-2 and HSV-1 co-infection are covered. Prevention is understood to mean amelioration of the extent of development of the relevant disease or infection in a subject treated with the virus, virion, vaccine or compositions described herein, as compared to an untreated subject.

[00133] Also provided is a method of producing a virion of a recombinant herpes simplex virus-2 (HSV-2), having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof and comprising an HSV-1 glycoprotein D on a lipid bilayer thereof, comprising infecting a cell comprising a heterologous nucleic acid encoding a HSV-1 glycoprotein D with a recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof under conditions permitting replication of the recombinant herpes simplex virus-2 (HSV-2) and recovering a recombinant HSV-2 virion comprising an HSV-1 glycoprotein D on a lipid bilayer thereof produced by the cell.

[00134] Also provided is a method of producing a virion of a recombinant herpes simplex virus-2 (HSV-2), having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof and comprising a non-HSV-2 surface glycoprotein on a lipid bilayer thereof, comprising infecting a cell comprising a heterologous nucleic acid encoding the non-HSV-2 surface glycoprotein with a recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof under conditions permitting replication of the recombinant herpes simplex virus-2 (HSV-2) and recovering a recombinant HSV-2 virion comprising a non-HSV-2 surface glycoprotein on a lipid bilayer thereof produced by the cell.

[00135] Also provided is a recombinant nucleic acid is provided having the same sequence as a genome of a HSV-2 except that the sequence does not comprise a sequence encoding an HSV-2 glycoprotein D.

[00136] Also provided is an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-2 infection in a subject.

[00137] Also provided is an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-1 infection in a subject.

[00138] Also provided is a virion of an isolated, recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof for treating or preventing an HSV-2 infection in a subject.

[00139] Also provided is a method of treating an HSV-1 infection, or HSV-1 and HSV-2 co-infection, in a subject, or treating a disease caused by an HSV-2 infection or HSV-1 and HSV-2 co-infection in a subject comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to treat an HSV-2 infection or treat a disease caused by an HSV-2 infection in a subject or an amount effective to treat an HSV-1 and HSV-2 co-infection or treat a disease caused by an HSV-1 and HSV-2 co-infection in a subject.

[00140] Also provided is a method of vaccinating a subject for an HSV-1 infection, or HSV-1 and HSV-2 co-infection, comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to vaccinate a subject for an HSV-1 infection, or HSV-1 and HSV-2 co-infection.

[00141] Also provided is a method of immunizing a subject against an HSV-1 infection, or HSV-1 and HSV-2 co-infection, comprising administering to the subject an amount of (i) a virus as described herein; (ii) a virion as described herein, (iii) a vaccine as described herein; (iv) a composition as described herein; or (v) a pharmaceutical composition as described herein, in an amount effective to immunize a subject against an HSV-1 infection, or HSV-1 and HSV-2 co-infection.

[00142] In an embodiment of the methods herein for immunizing, vaccinating or eliciting an immune response, passive transfer of the virion or virus or the antibodies or immune factors induced thereby may be effected from one subject to another. The relevant product may be treated after obtention from one subject before administration to a second subject. In a preferred embodiment of the inventions described herein, the subject is a mammalian subject. In an embodiment, the mammalian subject is a human subject.

[00143] A method is provided of eliciting an immune response in a first subject against an HSV-2 and/or HSV-1 infection, comprising passive transfer to the subject of an amount of a product from a second subject immunized with HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, wherein the product comprises the HSV-2 or the antibodies or immune factors induced thereby, effective to elicit an immune response against the HSV-2 and/or HSV-1 infection.

[00144] In embodiments, the product comprises serum of the second subject.

[00145] In embodiments, the second subject is a pregnant female.

[00146] In embodiments, the first subject is a fetus or neonate. In embodiments, the second subject is pregnant with the first subject.

[00147] In embodiments, the product comprises antibodies elicited by immunization of the second subject with the HSV-2.

[00148] Also provided is an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome thereof and further comprising a heterogenous antigen of a pathogen. In an embodiment, the heterogenous antigen is a protein, peptide, polypeptide or glycoprotein. In an embodiment, the heterogenous antigen heterogenous antigen with respect to HSV-2, but is an antigen found on or in the relevant "pathogen." Pathogens, viral and bacterial, are described herein. In an embodiment, the pathogen is a bacterial pathogen of a mammal or a viral pathogen of a mammal. In an embodiment, the antigen or the transgene encoding the pathogen is not actually taken or physically removed from the pathogen, but nevertheless has the same sequence as the pathogen antigen or encoding nucleic acid sequence. In an embodiment, the isolated, recombinant HSV-2 comprises a heterogenous antigen of a pathogen on a lipid bilayer thereof. In an embodiment of the isolated, recombinant HSV-2, the pathogen is bacterial or viral. In an embodiment, the pathogen is a parasite of a mammal. In an embodiment, the HSV-2 glycoprotein D-encoding gene is an HSV-2 *Us6* gene. In an embodiment, the isolated, recombinant HSV-2, the heterogenous antigen is encoded by a transgene that has been inserted into the genome of the recombinant HSV-2.

[00149] Also provided is a method of inducing antibody dependent cell mediated cytotoxicity (ADCC) against an antigenic target in a subject comprising administering to the subject an isolated, recombinant herpes simplex virus-2 (HSV-2) having a deletion of an

HSV-2 glycoprotein D-encoding gene in the genome thereof and further comprising a heterogenous antigen on a lipid bilayer thereof in an amount effective to induce antibody dependent cell mediated cytotoxicity (ADCC) against an antigenic target.

[00150] Recombinant HSV-2 $\Delta gD^{-/+}$ $gD^{-/+}$ expressing the appropriate transgenes will selectively induce antibodies and cellular immune responses that protect against skin or mucosal infections by pathogens.

[00151] In an embodiment, the heterogenous antigen is a surface antigen.

[00152] In an embodiment, the transgene encodes an antigen from an HIV, a *M. tuberculosis*, a *chlamydia*, *Mycobacterium ulcerans*, *M. marinum*, *M. leprae*, *M. absenscens*, *Neisseria gonorrhoea*, or a Treponeme. In an embodiment, the Treponeme is *Treponeme pallidum*. In an embodiment, the transgene is a *M. tuberculosis* biofilm-encoding gene. In an embodiment, the transgene is an HIV gp120-encoding gene.

[00153] In an embodiment, the heterogenous antigen is a surface antigen of the antigenic target. In an embodiment, the heterogenous antigen is a parasite antigen. In an embodiment, the heterogenous antigen is a bacterial antigen or a viral antigen.

[00154] In an embodiment, the antigenic target is a virus and is a Lassa virus, a human immunodeficiency virus, an RSV, an enterovirus, an influenza virus, a parainfluenza virus, pig corona respiratory virus, a lyssavirus, a bunyavirus, or a filovirus.

[00155] In an embodiment, the antigenic target is a bacteria and is *Mycobacterium tuberculosis*, *M. ulcerans*, *M. marinum*, *M. leprae*, *M. absenscens*, *Chlamydia trachomatis*, *Neisseria gonorrhoeae* or *Treponema pallidum*.

[00156] In an embodiment, the isolated, recombinant HSV-2 transgene is a *M. tuberculosis* biofilm-encoding gene or wherein the transgene is an HIV gp120-encoding gene.

[00157] In a preferred embodiment of the methods described herein, the subject is a human. In an embodiment of the methods described herein, the subject has not yet been infected with HSV-1, HSV-2 or co-infection. In an embodiment of the methods described herein, the subject has been infected with HSV-1, HSV-2 or co-infection.

[00158] As described herein, a co-infection means a co-infection with HSV-1 and HSV-2.

[00159] All combinations of the various elements described herein are within the scope of the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

[00160] This invention will be better understood from the Experimental Details, which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims that follow thereafter.

EXPERIMENTAL DETAILS

Example 1

[00161] Herein a genetically engineered deletion mutant of the *gD* (*Us6*) gene of HSV-2 is disclosed and its safety, immunogenicity, and vaccine efficacy evaluated against intravaginal HSV-2 challenge in the mouse infection model. The *gD* gene was replaced with a DNA fragment encoding the green fluorescent protein (*gfp*) and Vero cells expressing HSV-1 *gD* (VD60 cells) were transfected with this construct and screened for homologous recombinant virus that formed green plaques. Molecular analysis revealed that a precise recombination had been engineered, which replicates in the complementing VD60 cells to high titers but is noninfectious when propagated on non-complementing cells. Intravaginal challenge of wild-type or SCID mice with 10^7 pfu/mouse of the complemented *gD*-null virus (designated herein as HSV-2 $\Delta gD^{-/+}$ for the virus that is genotypically *gD* deleted, but phenotypically complemented by growth on VD60 cells) revealed no virulence, whereas doses as low as 10^4 pfu/mouse of parental wild-type virus were 100% lethal. Moreover immunization of mice with HSV-2 $\Delta gD^{-/+}$ yielded complete protection against intravaginal challenge with a clinical isolate of HSV-2. Robust humoral and cellular immunity elicited by HSV-2 $\Delta gD^{-/+}$ was measured and it is concluded that *gD* is required for productive infection *in vivo* and that an attenuated strain deleted in this essential glycoprotein elicits protective immunity against HSV-2. Thus, HSV-2 $\Delta gD^{-/+}$ is a promising vaccine for prevention or treatment of genital herpes.

[00162] Mechanisms and correlates of protection elicited by HSV-2 $\Delta gD^{-/+}$. A *gD*-2 null virus was generated, and it was demonstrated that it is highly attenuated in both immunocompetent and immunocompromised mice and when tested as a vaccine candidate, induced a protective immune response against intravaginal challenge with HSV-2. Subcutaneous immunizations with HSV-2 $\Delta gD^{-/+}$ will induce humoral and cellular immune responses that are required for protection against intravaginal challenge with both serotypes of HSV (HSV-2 and HSV-1).

[00163] HSV-2 ΔgD -/+ initiates an abortive infection: An HSV-2 strain that is deleted for *Us6* was constructed to assess its contribution in early signaling events occurring during cell infection [41]. This virus is incapable of infecting host cells, unless it is grown on a *gD*-complementing cell line (e.g. VD60 cells encoding *gD*-1 [40, 41]) that encodes *Us6* under the control of its endogenous promoter (for example, in an embodiment, the *gD*-1 promoter). Indeed, HSV-2 ΔgD particles isolated from non-complementing cells do not infect epithelial (Fig. 1) or neuronal cells (SK-N-SH, not shown). However, if propagated in VD60 cells a phenotypically complemented virus (ΔgD -/+) is obtained, which is fully capable of infecting cells that are common targets for wild-type HSV-2. However, after infection with ΔgD -/+ no infectious particles or viral plaques (pfu) are produced from these cells and the virus fails to spread from infected to uninfected cells, reflecting the requirement for *gD* in these processes; thus it is an abortive infection.

[00164] HSV-2 ΔgD -/+ is safe in the murine infection model: ΔgD -/+ was evaluated for safety *in vivo* in wild-type and severe combined immunodeficiency (SCID) mice by inoculating high doses subcutaneously or intravaginally. Mice inoculated intravaginally with 10^7 pfu of ΔgD -/+ (titered on complementing cells) did not manifest any signs of virus-induced pathology throughout the experiments, whereas animals inoculated with 1,000-fold less wild-type virus (10^4 pfu) succumbed to HSV-2 disease and died starting Day 8 after inoculation (Fig. 2A). Mice inoculated intravaginally with 10^7 pfu of ΔgD -/+ did not manifest any signs of virus-induced epithelial or neurological disease throughout the experiments (Fig. 2B and 2C). No infectious virus was recovered from genital tract tissue or DRGs, as determined by plaque assay or co-cultivation of DRGs with Vero cells (not shown).

[00165] HSV-2 ΔgD -/+ elicits systemic and mucosal antibodies to HSV-2: Mice inoculated and boosted subcutaneously (sc.-sc.) with ΔgD -/+ or inoculated subcutaneously and boosted intravaginally (sc.-i.vag.) with this candidate vaccine strain (10^6 pfu/mouse) elicited a humoral immune response to HSV-2 as evidenced by an increase in serum and vaginal washes anti-HSV-2 antibodies (Fig. 3A and 3B). The control animals were immunized with an uninfected VD60 cell lysate (referred to as Control). The antibodies were measured by ELISA using infected cell lysates as the antigen (response to uninfected cell lysates subtracted as background). Noteworthy, the magnitude of the antibody response differs depending on the route of immunization. Indeed, s.c.-s.c. immunization elicited significantly more serum and vaginal wash antibodies to HSV-2 than s.c.-i.vag.

immunization. This finding suggests that the vaginal wash antibodies likely represent transudate of IgG from the blood and suggest that sc.-sc. is a more appropriate route for eliciting high levels of systemic and local IgG antibodies to HSV-2. Additionally, Mice inoculated and boosted subcutaneously (sc.-sc.) with Δ gD-/+ (10^6 pfu/mouse) elicited a neutralizing anti-HSV-2 as evidenced by *in vitro* neutralization of Vero cell monolayers with virus and sera from these mice (Fig. 3C).

[00166] HSV-2 Δ gD-/+ elicits HSV-2-specific T cell activation: gB498-505-specific transgenic CD8+ T cells (gBT-I) were transferred into C57BL/6 mice prior to vaccination. Vaccinated mice were inoculated with 10^6 pfu Δ gD-/+ or with VD60 cell lysates (Control). Spleens were harvested on Day 14 after the boost and quantified by flow cytometry using counting beads (CountBright™, Lifetechnologies) (Fig. 4A). At the same day, spleens were stained for memory surface markers and analyzed by flow cytometry (Fig. 4B). Finally, splenocytes harvested the same day were re-stimulated *in vitro* for 6 hours with the agonist gB498-505-peptide and intracellular cytokine staining was performed to measure IFN- γ production by these cells. Immunization with Δ gD-/+ increased the IFN- γ production in the vaccinated compared to control mice (Fig. 4C). The response in control mice presumably reflects the persistence of the gBT-I T cells in naïve mice after transfer. Similar results were obtained using multiplex cytokine analyses for supernatants of splenocytes re-stimulated *in vitro* with gB498-505-peptide (not shown). These findings demonstrate that the vaccine induces T cell responses.

[00167] Mice immunized with HSV-2 Δ gD-/+ are protected against intravaginal HSV-2 lethal challenge: Animals vaccinated with HSV-2 Δ gD-/+ either sc.-sc. or sc.-i.vag. suffer less body weight after intravaginal lethal dose challenges equivalent to LD₉₀ (5×10^4 pfu/mouse) and survive challenges, whereas mice immunized with the VD60 control lysate succumbed to disease by Day 10 (Fig. 5A and 5B). The vaccines also provided complete protection against 10 times the LD₉₀ (5×10^5 pfu/mouse, data not shown). This protection was associated with significantly reduced epithelial disease scores (Fig. 5C) and the complete absence of neurological signs (Fig. 5D). Scoring was performed as previously described [44]. Furthermore, significantly less virus was recovered in vaginal washes in Δ gD-/+-immunized mice, as compared to control mice at day 2 post-vaginal challenge suggesting rapid clearance (Fig. 5E). Moreover no infectious virus was recovered in Day 4 vaginal washes (Fig. 5E) or in vaginal tissue or DRGs isolated on Day 5 after challenge

(Fig. 5F). The latter suggest that the vaccine prevents virus from reaching and/or replicating in the DRG.

[00168] Immunization with HSV-2 Δ gD-/+ prevents inflammation at the infection site after challenge with virulent HSV-2: Mice vaccinated with HSV-2 Δ gD-/+ and intravaginally challenged with virulent HSV-2 display significantly less inflammatory cytokines at the infection site as compared to animals inoculated with VD60 lysates (Control). Indeed, vaccinated mice secreted significantly less TNF- α (Fig. 6A), IL-6 (Fig. 6B) and IL-1 β (Fig. 6C) in vaginal washes at Day 2 and 7 post-infection than Control mice. Noteworthy, increased levels of inflammatory cytokines are associated with increased HIV replication and shedding at the genitalia in the co-infected with HSV-2 and HIV [45, 46]. A similar phenomenon is also observed *in vitro* [47].

[00169] Immunization with HSV-2 Δ gD-/+ recruits T cells to the infection site and associated LNs. Mice immunized sc.-sc. with Δ gD-/+ displayed increased percentages of activated anti-HSV-2 gBT-I CD8+ (Fig. 7A) and CD4+ T cells (Fig. 7B) in sacral lymph nodes (LNs) after challenge with virulent HSV-2. Mice immunized sc.-i.vag. with Δ gD-/+ displayed increased numbers of anti-HSV-2 gBT-I CD8+ (Fig. 7C) and CD4+ T cells (Fig. 7D) in the vagina after challenge with virulent HSV-2 suggesting that vaccination with Δ gD-/+ recruits anti-HSV-2 CD8+ T cells and activated CD4+ T cells (likely anti-HSV-2) to the infection site and associated lymph nodes.

[00170] In further experiments, immunization with HSV-2- Δ gD^{-/+gD-1} was found to confer protection in C57BL/6 and Balb/C to vaginal challenge with virulent HSV-2. In addition, intravaginal HSV-2 challenged Δ gD^{-/+gD-1} immunized mice had no detectable HSV-2 in vaginal or neural tissue at 5 days post-challenge. HSV-2 Δ gD-/+gD-1 sc.sc. antibodies were found to recognize numerous HSV-2 proteins (both gD and gB) unlike HSV-2 morbid-bound mice. Serum antibodies from vaccinated animals showed neutralization of HSV-1 and HSV-2 *in vitro*. Moreover, serum from Δ gD-/+gD-1 vaccinated mice elicited Antibody Dependent Cellular Cytotoxicity (ADCC) of HSV-2 infected cells *in vitro*.

[00171] In summary, HSV-2 Δ gD-/+gD-1 is attenuated and completely safe in wt and SCID mice. Recombinant HSV-2 Δ gD-/+gD-1 protected against lethal HSV-2 intravaginal and HSV-2/HSV-1 skin infection. Protection was observed in two different mouse strains. There was no detectable infection, and sterilizing immunity. Also observed was induction of HSV-2 specific CD8+ T cells and systemic and mucosal HSV Abs. IgG2a and IgG2b were

the predominant anti-HSV isotype. Also observed was FcγRIII/II-dependent ADCC. Surprisingly, passive transfer of immune serum protects naïve mice, and FcRn and FcγR knockout mice were not protected with immune sera.

Discussion

[00172] The World Health Organization estimated that over 500 million people were infected with herpes simplex virus type 2 (HSV-2) worldwide with approximately 20 million new cases annually [1]. Infection risk increases with age and because the virus establishes latency with frequent subclinical or clinical reactivation, the impact of infection is lifelong. Alarming, HSV-2 significantly increases the risk of acquiring and transmitting HIV [2-4]. The prevalence of HSV-2 varies among global regions, fluctuating from 8.4% for Japan up to 70% for sub-Saharan Africa, a region where HIV prevalence is epidemic [5, 6]. In the US the prevalence of HSV-2 is ~16% and that of HSV-1 has declined to ~ 54%. The decreasing prevalence of HSV-1 in the US (and other European nations) is linked to an increase in genital HSV-1 as evidenced by results in the recent disappointing glycoprotein D (gD) subunit vaccine trial in which the majority of cases of genital herpes disease were caused by HSV-1 [7-9]. While HSV-1 is associated with fewer recurrences and less genital tract viral shedding compared to HSV-2, both serotypes are transmitted perinatally and cause neonatal disease; neonatal disease is associated with high morbidity and mortality even with acyclovir treatment [10-12]. The morbidity associated with genital herpes, its synergy with the HIV epidemic, and its direct medical cost, which surpasses 500 million dollars in the US alone, highlight the imperative to develop a safe and effective vaccine [13].

[00173] Subunit formulations consisting of viral envelope glycoproteins combined with adjuvants have predominated the HSV-2 vaccine field for nearly 20 years and the majority of clinical trials have focused on this strategy [8, 14-19]. Although subunit preparations are safe and elicit neutralizing antibodies, these formulations provided little efficacy against HSV-2 infection or disease in clinical trials [8, 14]. Surprisingly, an HSV-2 gD subunit vaccine provided protection against genital HSV-1, but not HSV-2 [8, 20]. Subsequent studies found that serum HSV-2 gD antibody levels correlated with protection against HSV-1, suggesting that the antibody titers required for HSV-2 protection may be higher than those needed to protect against HSV-1 [21]. In contrast, cell mediated immunity (intracellular cytokine responses to overlapping gD peptides) did not correlate with

protection against either serotype [21]. The vaccine elicited CD4⁺, but not CD8⁺ T cell responses, but there were no differences in CD4⁺ T cell responses between vaccinated infected and uninfected women [21]. Genital tract or other mucosal antibody responses were not measured. An HSV-2 vaccine candidate with gH deleted from the genome failed to reduce the frequency of viral recurrences in a clinical trial conducted among seropositive subjects, although the vaccine was not evaluated for efficacy against primary infection [29].

[00174] Clinical studies showing increased rates of HSV-2 reactivation in HIV-infected patients combined with the failure of the gD subunit vaccine to elicit any CD8⁺ T cell response despite the induction of neutralizing serum antibodies suggest that an effective vaccine must also elicit protective T cell responses [28, 30-32]. The importance of T cells is further highlighted by studies showing selective retention of HSV-1 reactive T-cells in human trigeminal ganglia. CD4⁺ and CD8⁺ T cells were identified surrounding neurons and, while there was heterogeneity in the viral proteins targeted, the tegument protein, virion protein 16 (VP16), was recognized by multiple trigeminal ganglia T cells in the context of diverse HLA-A and -B alleles; these findings suggest that tegument proteins may be important immunogens [33]. Similarly, cytotoxic T cells directed at tegument proteins were also identified in studies of humans latently infected with HSV-2 [34]. CD8⁺ T cells (including CD8 α ⁺ T cells) persist in genital skin and mucosa at the dermal-epidermal junction following HSV reactivation suggesting that they play a role in immune control [35].

[00175] Herein is disclosed an engineered an HSV-2 virus genetically deleted for native HSV-2 gD. The HSV-2 *gD* gene encodes an envelope glycoprotein essential for viral entry and cell-to-cell spread. Glycoprotein D also binds to tumor necrosis factor receptor superfamily member 14 (TNFRSF14), an immune-regulatory switch also known as herpesvirus entry mediator (HVEM). Because HVEM harbors docking sites for more than one ligand and signaling differs depending on whether these molecules bind to HVEM in *cis* or in *trans*, gD may have modulatory effects on immune cells [36, 37]. Indeed, recent studies suggest that gD competes with the natural ligands for this receptor and modulates the cytokine response to the virus [38, 39]. The *gD* gene was replaced with a DNA fragment encoding the green fluorescent protein (*gfp*) and transformed complementing Vero cells expressing HSV-1 gD (VD60 cells [40]) (e.g. *gD-1* under *gD-1* promoter) with this construct were screened for homologous recombinant virus that formed green plaques. The mutant virus replicates in the complementing Vero cell line to high titers (designated HSV-2 Δ *gD*^{+/+}

when passaged on complementing cells), but is noninfectious in non-complementing cells (designated HSV-2 $\Delta gD^{-/-}$ when isolated from non-complementing cells). This virus was purified and characterized *in vitro* [41]. Intravaginal or subcutaneous inoculation of immunocompetent or immunocompromised (SCID) mice revealed no virulence compared to the lethal infection caused by parental wild-type virus. Immunization (subcutaneous prime followed by a single boost administered either subcutaneously or intravaginally) was 100% protective against intravaginal challenge with virulent HSV-2. Robust humoral and cellular immunity was elicited by HSV-2 $\Delta gD^{-/+}$ and it was concluded that *Us6* (*gD-2*) is required for productive infection *in vivo*. This live attenuated viral strain will provide sterilizing immunity against HSV. Also passive serum or serum product transfer can be employed.

Example 2

[00176] The ability of the vaccine to protect against clinical HSV-1 and HSV-2 isolates was further confirmed, as was the local immune response at the site of infection. Classically, HSV primarily infects genital or oral nucleated epidermal cells due to breaches in the skin or mucocutaneous layers in humans (75). To more closely model human HSV infection, a skin scarification model was used for these studies, which displays viral kinetics and histopathology similar to humans (76).

RESULTS

[00177] Immunization with low doses of $\Delta gD-2$ are protective against lethal intravaginal and skin challenges. Previous studies were conducted with 5×10^6 PFU (titer determined on complementing VD60 cells) of $\Delta gD-2$ as the vaccine inoculum. A dose de-escalation study was conducted to determine protection at lower doses of vaccination. C57BL/6 mice (5 mice/group) were subcutaneously (sc) primed and boosted 21 days later with 5×10^6 PFU, 5×10^5 PFU, or 5×10^4 PFU of $\Delta gD-2$. Three weeks later the mice were challenged either intravaginally or by skin scarification with an LD₉₀ (5×10^5 PFU) of HSV-2(4674), a previously described clinical isolate (77). All HSV-2 $\Delta gD-2$ immunized mice survived (5/5 per group), whereas all of the control-vaccinated mice (immunized with VD60 cell lysate) succumbed to disease (Fig. 8A, 8B). Although the mice vaccinated with the lowest dose (5×10^4) showed mild epithelial disease, no signs of neurological disease were observed and all animals completely recovered by day 14 in both the vaginal and skin challenge models.

HSV antibodies (measured by ELISA) were detected in the serum of all vaccinated mice one week after boost, but not prime, and the antibody titer increased with administration of higher vaccine doses (Fig. 8C).

[00178] Mice immunized with Δ gD-2 are protected from high viral challenges of virulent HSV-1 and HSV-2 clinical isolates. To evaluate if the Δ gD-2 vaccine protects against diverse HSV-1 and HSV-2 strains, five HSV-1 were obtained (denoted B3x1.1 - B3x1.5) and five HSV-2 (denoted B3x2.1 - B3x2.5) clinical isolates from the Clinical Virology Lab at Montefiore located in the Bronx, NY as well as a South African HSV-2 clinical isolate (SD₉₀). The isolates were grown on Vero cells and were passaged no more than three times before sequencing and phenotyping. Illumina sequencing showed that the strains exhibited substantial genetic diversity with pairwise distances as high as 6.3% between B3x1.5 and the other B3x1 isolates and 5.0% between B3x2.2 and the other B3x2 isolates. *In vivo* virulence of each clinical strain was compared to laboratory strains by challenging Balb/C mice using the skin scarification model with 1×10^5 PFU of the HSV-1 strains or 5×10^4 PFU of HSV-2 strains. The clinical isolates demonstrated a range of virulence with B3x1.1, B3x1.3, B3x2.3, and SD₉₀ inducing more rapid disease with the highest morbidity in naïve mice. Similar results were observed in the vaginal challenge model with the same 4 isolates exhibiting the most virulent disease (not shown). Interestingly, no differences between the isolates were observed by *in vitro* single and multistep growth curves on Vero cells.

[00179] To assess if Δ gD-2 protected against the different isolates, C57BL/6 or Balb/C mice were primed and boosted with 5×10^6 PFU/mouse of Δ gD-2 (or VD60 lysate as the control immunogen) and then challenged with an LD₉₀ dose of the 4 more virulent clinical isolates (Table 1) using the skin scarification model. All Δ gD-2 vaccinated mice survived challenge (n=7 C57BL/6 mice per group; Fig. 3A, and n=5 Balb/C mice per group, Fig. 9B). While some mice exhibited mild epithelial disease, which peaked on Day 4, the majority of animals had fully recovered by day 8 post-challenge. No signs of neurological disease were detected in any of the mice at any time point.

Table 1: HSV strains used in vaccine efficacy studies

Viral Strain	Origin of Isolate	HSV Serotype	Lethal Dose ₉₀ *
B ³ x1.1	United States	Type 1	5x10 ⁵ pfu
B ³ x1.3	United States	Type 1	1x10 ⁵ pfu
SD90	South Africa	Type 2	5x10 ⁴ pfu
B ³ x2.3	United States	Type 2	1x10 ⁵ pfu
4674	United States	Type 2	5x10 ⁵ pfu

Note: *Plaque forming units that cause 90% morbidity in Balb/C mice skin challenge model

[00180] To further evaluate the robustness of the immune response, the challenge dose was increased in the C57BL/6 mice to 10x and 100x the LD₉₀ doses of SD90 and 10x the LD₉₀ of B³x1.1. All of the ΔgD-2 vaccinated mice survived (Fig. 9D) with no signs of neurological disease. The ΔgD-2 vaccinated mice had significantly reduced virus detected in skin biopsies by day 5 post-challenge with the majority having no viral plaques detected (Fig. 10A, n= 3 mice per group). Consistent with the rapid clearance of virus, histopathology of skin biopsies revealed ulceration and necrosis covering 75-95% of the epithelium in control-vaccinated mice compared to <10% epithelial necrosis and ulceration in both the ΔgD-2 vaccinated mice and mock (unvaccinated, uninfected) treated mice. Moreover, there was no replicating or latent virus detected by plaque assay (Fig. 10B) or qPCR (Fig. 10C), respectively, in DRGs isolated on Day 14 post-challenge in the ΔgD-2 vaccinated mice (n=5 mice per each challenge dose and strain). Similarly, reactivating virus was not detected when DRGs from ΔgD-2 vaccinated mice (isolated Day 5 post-challenge with LD₉₀ of SD90) were co-cultured for 3 weeks with Vero cells. In contrast, viral DNA and reactivatable virus was recovered from all control (VD60 cell lysate)-vaccinated mice (DRG isolated at time of euthanasia) (Fig. 10D, n=5 mice per group).

[00181] HSV-2 ΔgD-2 recruits HSV-2 specific IgG2 antibodies and immune cells into the skin following challenge: To characterize the immune response to the vaccine and viral challenge in the skin, biopsies were obtained 21 days post boost and 2 or 5 days-post challenge and processed for histology and/or homogenized and then evaluated for presence of HSV-specific Abs by ELISA using either an HSV-2(4674) or HSV-1(17) infected cell lysate as the antigen. The ΔgD-2 immunized mice had low levels of HSV-specific Abs detected in the skin post-boost, which rapidly increased as early as day 2 post-challenge

(Fig. 11A). B3x1.1 elicited higher titer Ab response compared to SD90. As expected, no HSV-specific Abs were detected in the skin of control-vaccinated mice on Day 2 or Day 5 post-challenge (Fig. 11A and 11B). The Abs recovered from the skin were predominantly IgG [1:24,000 titer, (Fig. 11B)] with no detectable anti-HSV IgA or IgM (data not shown), and were enriched in IgG2 (equal induction of IgG2a and IgG2b) HSV specific antibodies (~80% of all HSV IgG) (Fig. 11C).

[00182] Murine IgG2 antibodies bind Fc γ R (78). The Abs elicited by the Δ gD-2 vaccine mediated ADCC and the studies were extended by measuring antibody-dependent-cellular-phagocytosis (ADCP) against HSV coated beads. Serum from Δ gD-2 vaccinated mice obtained 1 week post-boost elicited higher HSV specific phagocytosis and induced greater IFN- γ secretion compared to serum from control immunized mice or beads coated with cell lysates (Fig. 11D).

[00183] Skin biopsies from Δ gD-2-immunized and control vaccinated mice obtained on Day 5 post-challenge or unimmunized, uninfected mice (mock) were also evaluated by immunohistochemistry and/or immunofluorescence for immune cell responses. The Δ gD-2-immunized mice have a marked increase in CD3+ T cells (mean \pm SD 8.0% \pm 2.1 vs. 2.5% \pm 0.7, $p < 0.001$; Figure 12A, 12D) and B220+ B cells (3.8% \pm 1.1 vs; 2.4% \pm 1.1, $p = 0.09$; Fig. 12B, 12E) compared to control immunized mice. The T-cells were further characterized by staining for CD4 or CD8; there was a significant increase in the CD4+ population but not the CD8+ population in Δ gD-2 compared to control-immunized mice ($p < 0.05$) (Fig. 12F and 12G). Conversely, there was a decrease in Iba1+ monocyte/macrophage cells (Fig. 12C and 12H) and Ly6G+ neutrophils (Fig. 13) in Δ gD-2 compared to control immunized mice.

[00184] Consistent with the decrease in inflammatory cells and rapid clearance of virus, there was a decrease in inflammatory cytokines/chemokines detected in skin homogenates in the Δ gD-2 compared to control immunized mice on Day 5 post-challenge (Fig. 14). HSV-1 and HSV-2-infected mice had higher levels of TNF α (Fig. 14A), IL-1 β (Fig. 14B), and IL-6 (Fig. 14C) compared to mock-infected mice on Day 2 independent of immunization. However, the levels decreased by Day 5 in Δ gD-2 but not the control-immunized mice. Similar results were obtained for the chemokines CXCL9 (Fig. 14D) and CXCL10 (Fig. 14E). Interestingly, IL-33 levels were consistently higher in Δ gD-2-immunized compared to control-immunized mice at both time points (Fig. 14F).

DISCUSSION

[00185] This study further confirms that vaccination with HSV-2 Δ gD-2 affords complete protection against a panel of genetically diverse HSV-1 and HSV-2 clinical isolates and prevents the establishment of latency. Vaccine efficacy was confirmed in an optimized skin model, which is reflective of human primary disease. The Δ gD-2 elicited high titer antibodies that were rapidly recruited into the skin resulting in clearance of virus by day 5 even following challenge with 100-times the LD₉₀ of the most virulent strain, SD90. The protective effect of Δ gD-2 against a broad array of HSV-1 and HSV-2 clinical isolates differentiates it from other candidate vaccines such as HSV-2 Δ UL5/ Δ UL29, which failed to fully protect against the clinical isolate SD90, or gD subunit vaccines and others that have only been tested against one or two laboratory viral strains.

[00186] The broad protection afforded by Δ gD-2 likely reflects the unique nature of the immune response elicited. The Abs induced were enriched for the IgG2 subtype (~80% of all HSV-specific IgG), had low level neutralizing activity (not shown), were rapidly recruited into the skin with titers reaching 1:24,000 in skin biopsies by day 2 post-challenge, and mediated Fc effector functions (78) including ADCP (shown here) and ADCC. The antibody response to Δ gD-2 was dose-dependent, correlated with the rapidity of viral clearance as evidenced by disease scores and likely contributed to the vaccine's ability to completely prevent the establishment of latency. Although immunization with lower doses of Δ gD-2 elicited a lower titer of HSV-specific antibody in the serum, all of the mice were protected from lethal challenge. These findings suggest that lower levels of antibody may be sufficient for Fc γ R-effector functions. A different HSV-2 viral strain in which the nectin-1 binding domain of gD is altered (gD27), also elicited lower titers of serum neutralizing Abs compared to recombinant adjuvanted gD, but, conversely, was more protective than recombinant gD protein against vaginal challenge in mice (59). Other antibody functions such as ADCC or ADCP were not evaluated. However, these findings further support the notion that neutralizing Ab titers are not a predictive correlate of protection in mice, cotton rats (80), or humans.

[00187] While a rapid inflammatory response characterized by increases in cytokines and chemokines was observed in both control vaccinated and Δ gD-2 vaccinated mice on Day 2 post-challenge, the inflammatory response resolved in the vaccinated mice by Day 5, which is consistent with the rapid clearance of virus. In contrast, inflammation persisted in the control vaccinated mice, consistent with progressive disease. The latter was characterized

by persistently elevated cytokines/chemokines (IL-1 β , IL6, CXCL9 and CXCL10) and the persistence of monocytes/macrophages and neutrophils, which were observed throughout the epithelium and within the dermal layer in the control-vaccinated mice. In contrast, a higher percentage of CD4+ T cells and B220+ B cells were observed in the skin of Δ gD-2 vaccinated mice on Day 5, presumably reflecting a cellular memory response.

[00188] Interestingly, IL-33 was the only cytokine that trended higher in the skin from the Δ gD-2 immunized mice compared to controls. The precise role of IL-33 is not known. Prior studies have shown that rIL-33 administration enhanced skin wound healing in mice and was associated with activation of innate lymphoid cells and differentiation of monocytes into type 2 macrophages (81, 82). Systemic administration of IL-33 to mice was associated with an increase in Fc γ R2b, which is linked to decreased inflammation (88). Possibly, the increase in IL-33 observed in the skin of Δ gD-2 vaccinated mice promoted wound healing and resolution of inflammation.

[00189] The clinical isolates displayed variable virulence in the murine skin (and vaginal) model despite similar in vitro growth kinetics (76, 84). Interestingly, however, although a similar level of genetic diversity was seen among HSV-1 isolates to that described in previous studies, substantially greater genetic diversity was found among the HSV-2 isolates collected in the Bronx than those described in previous reports. The greater differences observed here may reflect the diverse geographic origins of the Bronx community. Despite this heterogeneity, all of the isolates tested were completely protected by Δ gD-2 vaccine, possibly reflecting the polyantigenic response. Moreover, complete protection was observed against both HSV-1 and HSV-2, which is clinically relevant, as HSV-1 has emerged as the more common cause of genital disease in the developed world. The universal protection observed here combined with the “sterilizing immunity” as evidenced by absence of latent virus supports the effectiveness of this Δ gD-2 vaccine.

MATERIAL AND METHODS

[00190] Cells and viruses: Vero (African green monkey kidney cell line; CCL-81; American Type Culture Collection (ATCC), Manassas, VA, USA) cells, VD60 cells [Vero cells encoding gD-1 under endogenous promoter (85)], and CaSki (human cervical epithelial cell line; CRL-1550; ATCC) were passaged in DMEM supplemented with 10% fetal bovine serum (FBS, Gemini Bio-Products, West Sacramento, CA). THP-1 (human monocyte cell line; TIB-202; ATCC) cells were passaged in RPMI-1640 (Life

Technologies) supplemented with 10% FBS and sub-cultured according to ATCC guidelines. Construction of HSV-2(G) Δ gD-2 and its propagation on VD60 cells has been previously described (95, 94). No variability in vaccine efficacy has been observed comparing 5 different viral preparations. HSV-2(4674) (86) was propagated on CaSki cells. Laboratory strains HSV-2(G) (87), HSV-2 (333-ZAG) (86), HSV-1(17) (89), and HSV-1(F) (87) were propagated on Vero cells. South African isolate HSV-2(SD90) (97) was provided by David Knipe and propagated on Vero cells. Five HSV-1 (B3x1.1 through B3x1.5) and five HSV-2 (B3x2.1 through B3x2.5) de-identified clinical isolates were provided by the Clinical Virology Lab at Montefiore and passaged three times on Vero cells for a low-passage working stock.

[00191] *In vitro* growth curves: Single-step and multi-step growth curves were performed as previously described (86). For single-step growth of each virus, Vero cells were infected with virus at a multiplicity of infection (moi) of 5 PFU/cell and supernatants and cells were collected every 4, 8, 16 and 24 hours (h) post-infection (pi) and stored at -80°C . For multi-step growth of each virus, Vero cells were infected at a moi of 0.01 PFU/cell and supernatants and cells were harvested every 12 h pi up to 72 hours. Infectious virus was measured by performing plaque assays with supernatants and lysed cells.

[00192] Viral DNA isolation and sequencing of clinical isolates: HSV DNA was prepared by infecting confluent Vero cells in a T150 flask with each of the B3x clinical isolates at an MOI of 10. Cells were harvested 16 hpi and washed twice with PBS. DNA was extracted using DNeasy® Blood and Tissue (Qiagen) following the manufacturer's recommendations. DNA was quantitated by Qubit dsDNA hs assay (Life Technologies). Paired-end libraries were prepared by the Nextera XT DNA library preparation kit (Illumina) following the manufacturer's instructions. Libraries were sequenced on an Illumina MiSeq Desktop Sequencer. Viral genome sequences were assembled with the VirAmp pipeline (89) following removal of host sequence by alignment to the *Macaca mulatta* genome as a substitute for the incomplete *Chlorocebus sabaues* (source of Vero cells) genome. HSV-1 and HSV-2 genomes were annotated with Genome Annotation Transfer Utility on ViPR by comparison to HSV-1(96) (GenBank accession no. JN555585.1) & HSV-2(HG52) (JN561323) prior to submission to GenBank. Whole genome alignments including the previously sequenced HSV-2 (SD90e) (KF781518), HSV-2 (333) (KP192856), ChHV 105640 (NC_023677.1), & HSV-1(F) (GU734771.1) were performed using ClustalW (90) and phylogenetic trees were constructed using the UPGMA

method with 1000 bootstrap replicates in MEGA6 (91). All positions containing gaps or missing data were eliminated. GenBank numbers for the genome sequences are as follows: HSV-2(G) (KU310668), HSV-2(4674) (KU310667), B3x1.1 (KU310657), B3x1.2 (KU310658), B3x1.3 (KU310659), B3x1.4 (KU310660), B3x1.5 (KU310661), B3x2.1 (KU310662), B3x2.2 (KU310663), B3x2.3 (KU310664), B3x2.4 (KU310665), B3x2.5 (KU310666).

[00193] Murine immunization and viral challenge studies: Experiments were performed with approval from Albert Einstein College of Medicine Institutional Animal Care and Use Committee, Protocol #20130913 and #20150805. Female C57BL/6 and BALB/c mice were purchased from Jackson Laboratory (JAX, Bar Harbor, ME) at 4-6 weeks of age. Mice were primed and boosted 3 weeks later with 5×10^4 - 5×10^6 PFU of Δ gD-2 or equal amount of VD60 cell lysates (Control) subcutaneously (sc, medial to the hind limb and pelvis) at 100 μ l/mouse. The titer was determined by a plaque assay on complementing cells (VD60).

[00194] For intravaginal HSV infections, mice were treated with 2.5 mg of medoxyprogesterone acetate (MPA; Sicor Pharmaceuticals, Irvine, CA) sc five days prior to challenge. Mice were then inoculated intravaginally with an LD₉₀ (5×10^5 pfu/mouse) of HSV-2 (4674) at 30 μ l/mouse and scored for disease and monitored for survival for 14 days as previously described (21). For HSV skin infections, mice were depilated on the right flank with Nair and allowed to rest for 24 hr. Depilated mice were anesthetized with isoflurane (Isothesia, Henry-Schein), then abraded on the exposed skin with a disposable emory board for 20–25 strokes and subsequently challenged with 1×10^5 PFU HSV-1 or 5×10^4 PFU HSV-2 strains for *in vivo* virulence studies or challenged with an LD₉₀, 10xLD₉₀, or 100xLD₉₀ of select HSV strains (see Table 1) for vaccine efficacy studies. Mice were monitored for 14 days and scored as follows: 1: primary lesion or erythema, 2: distant site zosteriform lesions, mild edema/erythema, 3: severe ulceration and edema, increased epidermal spread, 4: hind-limp paresis/paralysis and 5: death. Mice that were euthanized at a score of 4 were assigned a value of 5 on all subsequent days for statistical analyses.

[00195] HSV RT-qPCR: DNA was extracted from weighed tissue samples using DNeasy® Blood and Tissue (Qiagen) following the manufacturer's recommendations. Extracted DNA was then normalized to 10 ng of DNA per reaction and viral DNA quantified using real-time quantitative PCR (RT-qPCR, qPCR) using ABsolute qPCR ROX Mix (Thermo Scientific). Primers for HSV polymerase (UL30) were purchased from

Integrated DNA Technologies (Cat#: 1179200494) and used to detect viral genomic DNA. Isolated HSV-2 viral DNA was calibrated for absolute copy amounts using QuantStudio® 3D Digital PCR (dPCR, ThermoFisher Scientific) and subsequently used as a standard curve to determine HSV viral genome copies. Samples that read 4 or less copy numbers were considered negative. Data are presented as log₁₀ HSV genomes per gram of DRG (dorsal root ganglia) tissue.

[00196] Detection of antibodies and cytokines in skin biopsies: Skin biopsies were obtained from HSV-2 ΔgD-2 or VD60 lysates (control) immunized mice (~5-10 mm in diameter by mechanical excision) day 21 post-boost or day 2 and 5 post viral skin challenge. The tissue was weighed and homogenized in RNase/DNase free Lysing Matrix A tubes (MP Biomedicals, Santa Ana, CA) with serum-free DMEM at 6.0m/sec for three 30sec cycles in the FastPrep-24™ 5G (MP Biomedicals). Samples were spun at 5000 rpm for 10 min at 4°C and the resulting supernatant was evaluated for anti-HSV antibodies, cytokines and chemokines. Anti-HSV antibodies were detected by ELISA as previously described using uninfected, HSV-1(96), or HSV-2(4674)-infected Vero cell lysates as the coating antigen (94). Biotin anti-mouse Ig κ or biotin anti-mouse IgA, IgM, IgG1, IgG2a, IgG2b, or IgG3 at 1 μg/ml (Becton Dickenson, San Diego) were used as secondary detection antibodies. Wells were read on a SpectraMax (M5 series) ELISA plate reader at an absorbance of 450 nm. The resulting absorbance was determined by subtracting values obtained for uninfected cell lysates to values obtained with infected cell lysates. Total anti-HSV Ig is reported as the optical density (OD) at 450 nm normalized to relative tissue weight at a 1:1000 dilution of tissue homogenate. Anti-HSV IgG, IgA, IgM, or IgG1-3 are reported as the optical density (OD) at 450 nm at all dilutions except IgG1-3 which is reported only at a 1:100 dilution of skin homogenate.

[00197] Skin homogenate supernatants were assayed for interleukin-6 (IL-6), IL-1 beta (IL-1β), IL-33, tumor necrosis factor alpha (TNFα), monokine induced by interferon-gamma (MIG, CXCL9), interferon-inducible cytokine (IP-10, CXCL10) using a Milliplex mouse cytokine/chemokine immunoassay (Millipore, Danvers, MA) and a Luminex Magpix system and analyzed with Milliplex Analyst (Version 3.5.5.0; VigeneTech Inc.).

[00198] Histopathology, immunohistochemistry and immunofluorescence of skin tissue: Mice were euthanized on Day 5 post-challenge and the skin at the viral (or mock) infection site was excised and formalin fixed for 48hrs at RT. Samples were processed routinely to be paraffin-embedded and sectioned. Slides for histopathology were stained with hematoxylin

and eosin (H&E). Samples were evaluated histologically by a board certified veterinary pathologist which were blinded of samples identity. For immunohistochemistry (IHC), the samples were sectioned to 5 μm , deparaffinized in xylene followed by graded alcohols. Antigen retrieval was performed in 10 mM sodium citrate buffer at pH 6.0, heated to 96°C, for 30 minutes. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide in water. The sections were stained by routine IHC methods, using SuperPicTure™ (ThermoFisher Scientific, Cat:87-9673) against rabbit primary antibodies to anti-CD3 (Ready to use format, ThermoFisher Scientific, Cat: RM-9107-R7), anti-B220 (BD Biosciences Cat: 550286), or anti-Iba1 (1:3000 dilution Wako Pure Chemical Industries, Richmond, VA) and then stained with diaminobenzidine as the final chromogen. All immunostained sections were lightly counterstained with hematoxylin. Stained cross-sections were photomicrographed with Zeiss Axio Observer inverted light microscope at 20x magnification from apical layer (epidermal) to basal layer (striated muscle) at 3 different locations per sample. Stained-positive cells were enumerated as described by Bologna-Molina et al., 2011 (92). Data is represented as the average of %positive cells= (positive nucleated cells/total nucleated cells) of three photomicrographed sections per sample.

[00199] For Immunofluorescent studies, skin tissue was excised 5 days post-HSV or mock skin challenge and then frozen in OCT media. Samples were cut into 5 μm sections and stored at -80°C. Frozen slides were then fixed in -20°C acetone for 15 mins, washed with wash buffer (WB, 0.05% Tween 20 in PBS), then blocked for 2hrs with blocking buffer (2% BSA, 5% heat inactivated goat serum in PBS) at RT. Slides were washed twice and incubated with anti-CD4 (GK1.5, 1:200), anti-CD8 (YTS169.4, 1:250), anti-Ly6G (1A8, 1:500) in blocking buffer for 1 hr at RT. Slides were thoroughly washed and incubated with an goat anti-rat secondary antibody conjugated with either Alexa flour 555 or Alexa flour 488 (1:500 or 1:200, respectively) for 30 min at RT. Slides were washed and mounted with media containing DAPI (ProLong® Diamond Antifade Mountant with DAPI, ThermoFisher Scientific). Slides were imaged using a Nikon Eclipse Ti-U inverted light microscope at 20x magnification from apical layer (epidermal) to basal layer (striated muscle) at two different locations per sample. For %CD4+ and %CD8+ quantification, total nucleated cells were calculated by DAPI positive objects $\geq 5\mu\text{m}$ via a software algorithm from Velocity (version 6.3, Perkin Elmer). CD4 or CD8 positive cells were counted manually for fluorescence and incorporation of a DAPI+ nuclei to exclude non-specific

staining of hair follicles and cellular debris in the skin sections. Data is represented as the average of %positive cells= (positive cells/total DAPI cells) of two images per sample.

[00200] Antibody dependent cellular phagocytosis (ADCP) assay. To determine HSV specific ADCP, a protocol modified from Ackerman et al., 2011 (93) was used. Briefly, 2×10^8 $1 \mu\text{m}$ Neutravidin-red fluorescent beads (Invitrogen, F-8775) were coated with 0.3mg of biotinylated HSV-2 infected or uninfected (control) Vero cells overnight at 4°C in $500 \mu\text{l}$ of BlockAid™ (ThermoFisher Scientific, B-10710). Beads were washed twice with 1% BSA in PBS and then 1×10^6 beads/well were added in a 96 round bottom plate. Serum from immunized mice at 1 week post boost was heat-inactivated at 56°C for 30 min and diluted 1:5 in serum-free RPMI. $50 \mu\text{l}$ of diluted serum was added to wells that contained the HSV lysates or control cell lysates coated beads and incubated for 2 h at 37°C . 2×10^4 cells/well THP-1 cells were added to each at a final volume of $200 \mu\text{l}$ /well and incubated for 8 hr at 37°C at 5% CO_2 . Subsequently, $100 \mu\text{l}$ of supernatant was removed and stored at -20°C then resuspended with $100 \mu\text{l}$ 4% paraformaldehyde. Samples were then read on 5-laser LSR II flow cytometer (Becton Dickinson, San Diego) at the Einstein Flow Cytometry Core Facility. Phagocytic score is reported by gating on events representing THP-1 cells then applying the following equation: [(% of cells bead positive X MFI of cells positive for beads)/ 10^6] using FlowJo software (version 10, Tree Star Inc.). IFN- γ secretion from activated THP-1 cells via antibody phagocytosis was determined by analyzing stored cultured supernatants using a Milliplex human custom immunoassay (Millipore, Danvers, MA) and a Luminex Magpix system as previously described.

[00201] Virus detection in tissue. Skin and dorsal root ganglia (DRG) were weighed and homogenized as described above. Supernatants of homogenized tissue were then overlaid on confluent Vero cell monolayers (2×10^5 cells/well in a 48-well plate) for 1 h. Wells were washed with PBS and then with 199 medium (Gibco®) containing 1% heat-inactivated FBS, overlaid with 0.5% methylcellulose and incubated at 37°C for 48 h. Cells were fixed with 2% paraformaldehyde, stained with a crystal violet solution and the number of PFU quantified. Neuronal *ex-vivo* co-culture assays were performed as previously described (94).

[00202] Statistical analysis. Results were compared by two-way analysis of variance (2-way ANOVA) with multiple comparisons or unpaired student's t-tests using GraphPad Prism version 6 (San Diego, CA). Mantel-Cox survival curves were compared by log rank tests. P values <0.05 (*), <0.01 (**), <0.001 (***) were considered significant.

Example 3

[00203] Neonatal HSV infection, worldwide, is about 14,000 cases/yr. Primary maternal genital HSV accounts for 50-80% of neonatal cases. Perinatal transmission with either results in severe mortality and morbidity even with effective therapy. It is apparent that pre-existing maternal antibodies can apparently provide some protection since the risk of perinatal HSV transmission decreases to 1-3% with recurrent maternal HSV disease. However, there are an increasing number of pregnant women who are seronegative for both HSV1/2.

[00204] Mice and ethics statement: Murine studies were approved by the Institutional Animal Care and Use Committee at Albert Einstein College of Medicine, Protocol #2016-1205. C57BL/6 mice were purchased from Jackson Laboratory (JAX, Bar Harbor, ME).

[00205] Cells and viruses: Vero (African green monkey kidney cell line; CCL-82; ATCC), HaCAT (human keratinocytes, ATCC CLS 300493) and VD60 cells (Vero cells encoding gD-1 under its endogenous promoter) were passaged in DMEM supplemented with 10% fetal bovine serum (FBS, Gemini Bio-Products, West Sacramento, CA) and 1% penicillin-streptomycin (Invitrogen). The clinical isolates, HSV-2 (4674) and HSV-1 (B3x1.1), and the laboratory strain, HSV-2 (333) ZAG, which expresses green fluorescence protein (GFP) under control of the CMV promoter inserted at an intergenic site within the virus were propagated on Vero cells. HSV-2(G) Δ gD-2 was propagated on complementing gD-1 expressing VD60 cells and viral titers determined by plaque assays on VD60 and Vero cells in parallel; no plaques were detected on the non-complementing Vero control cells.

[00206] Immunizations and viral challenge studies: Female mice were vaccinated with 5×10^6 pfu of Δ gD-2 (grown on VD60 cells), uninfected control VD60 cell lysates, or $5 \mu\text{g}$ of recombinant gD-2 protein combined with $150 \mu\text{g}$ of aluminum (Alum) (Imject Alum; Pierce Biotechnology, Rockland, IL) and $12.5 \mu\text{g}$ of monophosphoryl lipid A (MPL) (Invivogen, San Diego, CA) (rgD-2/Alum-MPL). Vaccines were administered subcutaneously at 4 weeks of age (prime) and a 7 weeks (boost) in a final volume of $100 \mu\text{l}$ /mouse. One week after boost, immunized females were housed with males (2:1) and monitored for a vaginal plug. Male mice were subsequently removed and the pregnant females monitored daily until delivery. Pups were inoculated intranasally on days 1, 7 or 14 of life with $5 \mu\text{l}$ of virus administered by micropipette to both nares at a does that resulted in 90% lethality (LD90) in unvaccinated 7 day-old neonatal mice (LD90) (typically $\sim 10^5$ pfu/mouse of HSV-1 (B3x1.1) or 10^3 - 10^4 pfu/mouse HSV-2 (4674)). Pups were monitored daily for signs of disease and

were immediately euthanized if they developed signs of encephalitis (e.g. paralysis, tremors, gait instability, hunched posture).

[00207] Detection of HSV DNA by quantitative polymerase chain reaction (qPCR): At time of euthanasia (when mice succumbed to disease or day 14 post-challenge), trigeminal ganglia were collected, DNA was extracted using DNeasy Blood and Tissue (Qiagen) and 10 ng DNA per sample was assayed for presence of HSV by real-time qPCR (Absolute qPCR ROX Mix (Thermo Scientific) using primers that target HSV polymerase (UL30) (forward primer sequence, 5'-GGCCAGGCGCTTGTTGGTGTA-3' (SEQ ID NO:3); reverse primer sequence, 5'-ATCACCGACCCGGAGAGGGA-3' (SEQ ID NO:4); probe sequence, 5'-CCGCCGAAGTGGAGCAGACACCCGC-3' (SEQ ID NO:5))(Integrated DNA Technologies). Mouse β -actin was used as a loading control (Applied Biosystems, Foster City, CA) and qPCR was run in an Applied Biosystems QuantStudio 7 Flex. Samples with fewer than four copies were considered negative.

[00208] Quantification of antibody responses, neutralizing titers and Fc γ R activation: HSV-specific total or isotype specific IgG were determined by a previously described enzyme-linked immunosorbent assay (ELISA) in serum or in breastmilk. Breastmilk was collected from pregnant female mice on days 8-12 post-parturition by separating them from their offspring for at least 2 hours and administration of a single-dose of 2 IU/kg of oxytocin via intraperitoneal injection 5 minutes before milking. Droplets of milk were manually expressed and then pipetted into sterile Eppendorf tubes and frozen at -20°C until use. Briefly, ELISA plates were coated with Vero cell lysates harvested 24 h after infection with HSV-1(B3x1.1) or HSV-2(4674) at a multiplicity of Infection (MOI) of 0.1 pfu/cell or uninfected control lysates. Serial dilutions of serum were incubated with the coated plates overnight at 4°C and bound IgG, IgG1, IgG2, or IgG3 was quantified using specific biotin-labeled secondary Abs (BD Biosciences, San Jose, CA). The anti-HSV IgG level was determined after subtracting optical densitometry (OD) values obtained for uninfected cell lysates. The neutralization titer was defined as the highest heat-inactivated serum dilution to result in 50% reduction in the number of plaques relative to plaques formed in the absence of immune serum (~100 plaques per well). Fc γ RIV activation was determined using the mFc γ IV ADCC Reporter Bioassay (Promega, Madison, WI) with HSV-2(4674) or HSV-1(B3x1.1)-infected Vero cells as the targets.

[00209] Antibody-Dependent Cell-Mediated Killing (ADCK) assay: Effector immune cells were isolated from spleens and livers and pooled from 5-10 naïve neonatal or 3-5

naïve adult mice. Red blood cells were removed by lysis with ammonium-chloride-potassium (ACK) lysis buffer (Gibco, Grand Island, NY). Pooled cells were counted and resuspended in complete RPMI media. Target cells were HaCaT cells infected for 4 h at 37°C with a MOI of 1 pfu/cell of HSV-2 (333) ZAG, or as a control, uninfected HaCaT cells. The targets were dissociated with CellStripper (Corning), resuspended at 10^7 cells/ml in DMEM and 2×10^5 cells (in 100 μ l) were added to each well of a 96-well U bottom plate. The targets were incubated with pooled heat-inactivated serum (1:5 dilution in DMEM) isolated from Δ gD-2 or VD60 control vaccinated adult mice for 15 minutes at room temperature. The pooled effector cells were then added at an effector to target cell ratio of 10:1 for 1 hr. The cultures were stained with Live/Dead Red fixable dye (Invitrogen) for 30 min, fixed with 5% paraformaldehyde in phosphate buffered saline (PBS) and resuspended in FACS buffer (2% heat-inactivated FBS in PBS). The cells were analyzed by flow cytometry on an LSRII (Becton Dickinson) and the percentage of GFP-positive (HSV-2 infected) dead cells was determined using FlowJo analysis software.

[00210] Fc γ R expression: Immune cells isolated as for the ADCK assay from spleens and livers of adult or neonatal mice were adjusted to 1×10^7 cells/mL in FACS Buffer and 100 μ l of cell suspension was added to a 96-well round-bottom microtiter plate. Cells were stained for 30 minutes at 4°C in the dark with CD11b-APC-Cy7, Ly6G-AlexaFluor700, Ly6C-PE, F4/80-APC, CD3-PE-Cy7, Live/dead Red fixable dye (BD Biosciences, Invitrogen) and relevant anti-mFc γ -FITC (I, II, III, IV; BioLegend) and then fixed with 4% paraformaldehyde in PBS for 15 min. For analysis, doublets were excluded based on forward and side light scatter area (FSC-A, SSC-A) versus width (FSC-W, SSC-W). Cell populations were defined as follows: macrophages, CD11b^{int}F4/80^{hi}; neutrophils, CD11b^{hi}F4/80^{lo}Ly6G^{hi}Ly6C^{int}; monocytes, CD11b^{hi}F4/80^{lo}Ly6G^{int}Ly6C^{hi}. Samples were read on LSRII flow cytometer (BD Biosciences) and data were analyzed using FlowJo analysis software. The percent of Fc γ R positive cells was calculated based on %FMO FITC positive-%FITC positive.

[00211] Statistical Analysis: Statistical analyses were performed using GraphPad Prism version 7.0 software (GraphPad Software Inc., San Diego, CA). A p value less than or equal to 0.05 was considered statistically significant. Survival curves were compared using Mantel-Cox test; other results were compared using analysis of variance with multiple testing as indicated.

RESULTS

[00212] Maternal vaccination with Δ gD-2 protects 7-14 day old pups from HSV-1 or HSV-2 challenge: To determine if maternal vaccination could protect pups from HSV postnatally, adult female mice were vaccinated with two doses of Δ gD-2, rgD-2/Alum-MPL, or as a control, an uninfected VD60 cell lysate prior to mating, and their pups challenged intranasally with clinical isolates of HSV-1 or HSV-2 at an ~LD90 dose. Pups were initially challenged on day of life 7, which is presumed to correspond immunologically to a term human infant. Significant protection against lethal HSV-1 and HSV-2 disease was observed in pups born to Δ gD-2 immunized dams compared to pups born to control-vaccinated dams ($p < 0.001$) (Fig. 15A). In contrast, maternal rgD-2/Alum-MPL provided little protection against HSV-1 (1/5 (20%) survival) or HSV-2 (3/18 (16.7% survival) in 7 day old pups. Protection persisted when pups were challenged on Day 14 of life (Fig. 15B, $p < 0.001$), but was diminished (more diminished for HSV-2 than HSV-1) when pups were challenged on Day 1 of life (Fig. 15C).

[00213] To determine whether the protection against lethal disease observed in 7 or 14 day old pups was associated with protection against the establishment of a latent reservoir, trigeminal ganglia were assayed for HSV DNA by qPCR either at time of demise or, in the surviving mice, on day 14 post-viral challenge. There was a significant reduction in viral DNA recovered from pups born to dams vaccinated with Δ gD-2 compared to mice vaccinated with rgD2-Alum/MPL or VD60 control lysates, which is suggestive of rapid viral clearance by maternally derived Abs. (See Fig. 17).

[00214] Protection correlates with Fc γ RIV- activating antibodies: HSV binding (ELISA), neutralizing and Fc γ RIV activating Ab levels were quantified in blood obtained from pups who were infected on Day 7 of life with HSV-1 or HSV-2 at time of euthanasia for disease (mean Day 6 post-challenge) or at the end of the experiment for pups who survived challenge (Day 14 post-challenge). Vaccination with gD-2/Alum-MPL and Δ gD-2 elicited similar titers of HSV-1 or HSV-2 binding IgG Abs whereas, as expected, little or no HSV-specific IgG was detected in HSV-infected pups born to VD60 immunized mice (Figs. 16A, 16B). However, the functionality of the Abs differed. The Abs in serum of pups born to dams immunized with gD-2/Alum-MPL were predominantly neutralizing (mean NT 1:25) (Fig. 16C) but did not activate the murine Fc γ RIV (Fig. 16D). Conversely, the serum Abs in mice born to Δ gD-2-immunized dams displayed significant Fc γ RIV activation indicative of ADCC activity, but little or no neutralizing activity.

[00215] Optimal protection requires antibodies acquired from breastmilk: The difference in protection observed when pups were challenge on Day 1 of life compared to Day 7 or 14 suggests that transplacentally acquired antibodies alone are not sufficient and/or there are age-dependent differences in Fc γ R effector cell function(s). To explore these possibilities, pups born to Δ gD-2-immunized mothers were switched at birth and nursed by mothers who had been immunized with VD60 cell lysates (only transplacentally-acquired Abs) and, conversely, mice born to VD60 control-immunized mothers were nursed by Δ gD-2-immunized mothers (only breastmilk-acquired Abs). Positive controls were mice that were both born to and nursed by Δ gD-2-immunized mothers and negative controls were mice that were born to and nursed by VD60 control lysate-immunized mothers. The pups were then challenged intranasally on Days 7 or 14 of life and monitored for two weeks. Compared to controls (pups born to and nursed by a VD60-immunized dam), pups born to a Δ gD-2-immunized dam were significantly protected from an LD90 of HSV-1 when challenged on Day 7 or 14 if they were also nursed by a Δ gD-2 immunized dam, but not if the pups were switched at birth and nursed by a control-immunized dam ($p < 0.001$, Kaplan-Meier with correction for multiple comparisons). Conversely, pups born to a VD60-immunized dam, but nursed by a Δ gD-2 immunized mouse were also significantly protected when challenged on Day 14, but not on Day 7 ($p < 0.001$). Similar results were obtained when pups were challenged with HSV-2. (Figs. 19A-C) Protection against latency is also optimal in neonates which have received both transplacental and breastmilk Abs. (Fig. 20)

[00216] Results correlated with the amount of neonatal Ab levels present in the pup's serum at time of challenge. (Figs. 21A-21B) For these studies, blood was obtained on Days 3, 7 or 14 in "switched" mice who were not challenged with virus. (Collection of blood on Day 1 was not feasible). Neonatal levels of HSV-2 specific IgG rapidly declined if mice were born to, but not nursed by a Δ gD-2 immunized mother, which is consistent with the short half-life of murine IgG. Conversely, HSV-specific IgG increased rapidly in mice that were only nursed by a Δ gD-2 immunized mother. The presence of HSV-specific antibodies in breastmilk was confirmed in samples collected on Days 8-12.

[00217] Decreased protection in mice challenged on day 1 is linked to antibody-dependent cell killing activity: Despite the presence of a sufficient level of HSV-specific Abs on Day 1 of life (based on levels measured on Day 3 in pups born to but not nursed by a Δ gD-2 immunized mother), protection was not statistically significant suggesting differences in Fc γ RIV expression and/or defects in antibody dependent cell killing (ADCK).

No significant differences in the expression of any of the Fc γ R_s were observed in immune cell sub-populations isolated from the livers and spleens of 1-3 day old compared to adult mice. However, the ADCK effector function of the immune cells isolated from 1-3 day old pups was significantly reduced compared to Day 7 or adult cells. For these studies, pooled single cell suspensions of immune cells isolated from different aged mice (effector cells) were incubated with HSV-2(ZAG)(which expresses GFP)-infected HaCAT target cells in the presence of serum harvested from Δ gD-2 or VD60 immunized adult mice and the ability of the effector cells to kill the target cells was quantified. (Data not shown).

[00218] Convalescent serum from mice infected with a sublethal dose of HSV-2 failed to protect pups from subsequent viral challenge. Adult female mice (C567BL/6) were infected intranasally with a dose of 10^5 pfu HSV-2 (4674) or with PBS (control). Two weeks after infection, serum was collected from the mice and tested for HSV-2 specific antibodies. Sublethal infection induced an IgG response (Fig. 22A, ELISA titer) that was predominantly neutralizing (Fig. 22B) with little Fc γ R_{IV} activation compared to Δ gD-2 vaccinated mice (Fig. 22C). The seropositive or control mice were subsequently mated and the resulting pups were challenged intranasally on Day 7 with HSV-2. No significant protection was observed (Fig. 22D).

DISCUSSION

[00219] Globally, it is estimated that HSV infects 10 per 100,000 births with most cases occurring in Africa reflecting a high incidence of maternal HSV-2. However, the highest overall prevalence may be in the Americas where a growing number of HSV-1 and HSV-2 seronegative women reach reproductive age thus rendering them at greater risk of acquiring primary genital infection with either serotype. Suppressive acyclovir treatment for women with a history of frequent recurrences and/or Caesarean section if active lesions are detected at time of labor may reduce the risk of HSV but most perinatal transmission occurs in the setting of primary maternal HSV and in the absence of clinical lesions. Thus, optimal prevention will require a vaccine that is effective against clinical isolates of both HSV-1 and HSV-2 and that generates IgG responses that efficiently cross the placenta.

[00220] Results of the current murine studies demonstrate that immunization of female adult mice (prior to conception) with Δ gD-2 elicits Ab responses that protect neonatal mice (7-14 days of life) from intranasal viral challenge with clinical isolates of HSV-1 or HSV-2. Protection correlates with the ability of the Abs to activate the murine Fc γ R_{IV} to elicit

ADCK. Despite generating similar levels of total HSV-specific Abs in serum of neonatal mice, maternal immunization with adjuvanted recombinant gD-2 protein provided only limited protection on Day 7, but significant protection was observed on Day 14 paralleling an increase in HSV-specific antibodies acquired from breastmilk. These findings are supported by the clinical observation that neutralizing Abs, which are the dominant response to natural infection, provide partial protection against neonatal disease.

[00221] Some protection (not statistically significant) was apparent on day of birth neonates (see Fig. 15C). However, protection was optimal when neonatal mice received both transplacental and breast milk-acquired Abs as evidenced by the loss of protection in pups born to Δ gD-2 immunized dams were switched at birth and nursed with control vaccinated mice. This reflects the relatively short half-life of murine IgG, which is ~6-8 days for IgG1, IgG2a/c and IgG3 and 4-6 days for IgG2b, as well as the higher levels of Fc neonatal receptor expression on the brush border of the proximal small intestine in mice. In contrast, the half-life of human IgG is much longer and infants, as fetuses, receive most of their maternal IgG transplacentally because of the relatively high levels of expression of the neonatal FcR in the syncytiotrophoblasts. Accordingly, the fetal protection (transplacental) in mouse under-represents the protection that is obtainable by the technique in fetal and neonatal humans.

[00222] It is clear that prevention of perinatal infections can be achieved through maternal immunization strategy, and that passive transfer of antibodies protected naïve animals.

REFERENCES

1. Looker, K.J., G.P. Garnett, and G.P. Schmid, An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. *Bull World Health Organ*, 2008. **86**(10): p. 805-12, A.
2. Freeman, E.E., et al., Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. *AIDS*, 2006. **20**(1): p. 73-83.
3. Gray, R.H., et al., Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. *Lancet*, 2001. **357**(9263): p. 1149-53.

4. Wald, A. and K. Link, Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. *J Infect Dis*, 2002. **185**(1): p. 45-52.
5. Paz-Bailey, G., et al., Herpes simplex virus type 2: epidemiology and management options in developing countries. *Sex Transm Infect*, 2007. **83**(1): p. 16-22.
6. Doi, Y., et al., Seroprevalence of herpes simplex virus 1 and 2 in a population-based cohort in Japan. *J Epidemiol*, 2009. **19**(2): p. 56-62.
7. Bradley, H., et al., Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. *J Infect Dis*, 2014. **209**(3): p. 325-33.
8. Belshe, R.B., et al., Efficacy results of a trial of a herpes simplex vaccine. *N Engl J Med*, 2012. **366**(1): p. 34-43.
9. Bernstein, D.I., et al., Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. *Clin Infect Dis*, 2013. **56**(3): p. 344-51.
10. Kimberlin, D., Herpes simplex virus, meningitis and encephalitis in neonates. *Herpes*, 2004. **11** Suppl 2: p. 65A-76A.
11. Ward, K.N., et al., Herpes simplex serious neurological disease in young children: incidence and long-term outcome. *Arch Dis Child*, 2012. **97**(2): p. 162-5.
12. Lafferty, W.E., et al., Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. *N Engl J Med*, 1987. **316**(23): p. 1444-9.
13. Owusu-Edusei, K., Jr., et al., The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. *Sex Transm Dis*, 2013. **40**(3): p. 197-201.
14. Mertz, G.J., et al., Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. *J Infect Dis*, 1990. **161**(4): p. 653-60.
15. Group, H.S.V.S., et al., Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial. *Vaccine*, 2013. **31**(51): p. 6136-43.
16. Leroux-Roels, G., et al., Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. *Hum Vaccin Immunother*, 2013. **9**(6): p. 1254-62.

17. Bernstein, D.I., et al., Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. *Clin Infect Dis*, 2005. 40(9): p. 1271-81.
18. Stanberry, L.R., et al., Glycoprotein-D-adjuvant vaccine to prevent genital herpes. *N Engl J Med*, 2002. 347(21): p. 1652-61.
19. Corey, L., et al., Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. *JAMA*, 1999. 282(4): p. 331-40.
20. jh.richardus@rotterdam.nl, Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: Results from a randomised, controlled, double-blind trial. *Vaccine*, 2013. 31(51): p. 6136-43.
21. Belshe, R.B., et al., Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women. *J Infect Dis*, 2013.
22. Gerber, S.I., B.J. Belval, and B.C. Herold, Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism. *Virology*, 1995. 214(1): p. 29-39.
23. Lubinski, J.M., et al., The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. *J Virol*, 2011. 85(7): p. 3239-49.
24. Para, M.F., L. Goldstein, and P.G. Spear, Similarities and differences in the Fc-binding glycoprotein (gE) of herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein. *J Virol*, 1982. 41(1): p. 137-44.
25. Hook, L.M., et al., Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody. *J Virol*, 2006. 80(8): p. 4038-46.
26. Lubinski, J.M., et al., Herpes simplex virus type 1 evades the effects of antibody and complement in vivo. *J Virol*, 2002. 76(18): p. 9232-41.
27. Awasthi, S., et al., Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. *J Virol*, 2011. 85(20): p. 10472-86.

28. Manservigi, R., et al., Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. *Vaccine*, 2005. **23**(7): p. 865-72.
29. de Bruyn, G., et al., A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. *Vaccine*, 2006. **24**(7): p. 914-20.
30. Ouwendijk, W.J., et al., T-cell immunity to human alphaherpesviruses. *Curr Opin Virol*, 2013. **3**(4): p. 452-60.
31. Parr, M.B. and E.L. Parr, Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes. *J Virol*, 1998. **72**(4): p. 2677-85.
32. Noisakran, S. and D.J. Carr, Lymphocytes delay kinetics of HSV-1 reactivation from in vitro explants of latent infected trigeminal ganglia. *J Neuroimmunol*, 1999. **95**(1-2): p. 126-35.
33. van Velzen, M., et al., Local CD4 and CD8 T-cell reactivity to HSV-1 antigens documents broad viral protein expression and immune competence in latently infected human trigeminal ganglia. *PLoS Pathog*, 2013. **9**(8): p. e1003547.
34. Muller, W.J., et al., Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. *J Gen Virol*, 2009. **90**(Pt 5): p. 1153-63.
35. Zhu, J., et al., Immune surveillance by CD8 α α ⁺ skin-resident T cells in human herpes virus infection. *Nature*, 2013. **497**(7450): p. 494-7.
36. Steinberg, M.W., et al., Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. *Semin Immunopathol*, 2009. **31**(2): p. 207-21.
37. Steinberg, M.W., T.C. Cheung, and C.F. Ware, The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. *Immunol Rev*, 2011. **244**(1): p. 169-87.
38. Kopp, S.J., C.S. Storti, and W.J. Muller, Herpes simplex virus-2 glycoprotein interaction with HVEM influences virus-specific recall cellular responses at the mucosa. *Clin Dev Immunol*, 2012. **2012**: p. 284104.

39. Yoon, M., et al., Functional interaction between herpes simplex virus type 2 gD and HVEM transiently dampens local chemokine production after murine mucosal infection. *PLoS One*, 2011. 6(1): p. e16122.
40. Ligas, M.W. and D.C. Johnson, A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells. *J Virol*, 1988. 62(5): p. 1486-94.
41. Cheshenko, N., et al., HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression. *FASEB J*, 2013. 27(7): p. 2584-99.
42. Parr, E.L. and M.B. Parr, Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. *J Virol*, 1997. 71(11): p. 8109-15.
43. Mbopi-Keou, F.X., et al., Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2. *Clin Diagn Lab Immunol*, 2003. 10(3): p. 388-93.
44. Hendrickson, B.A., et al., Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection. *Virology*, 2000. 271(1): p. 155-62.
45. Nixon, B., et al., Genital Herpes Simplex Virus Type 2 Infection in Humanized HIV-Transgenic Mice Triggers HIV Shedding and Is Associated With Greater Neurological Disease. *J Infect Dis*, 2013.
46. Carr, D.J. and L. Tomanek, Herpes simplex virus and the chemokines that mediate the inflammation. *Curr Top Microbiol Immunol*, 2006. 303: p. 47-65.
47. Stefanidou, M., et al., Herpes simplex virus 2 (HSV-2) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy. *J Virol*, 2013. 87(3): p. 1443-53.
48. Bourne, N., et al., Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. *J Infect Dis*, 2003. 187(4): p. 542-9.
49. Bourne, N., et al., Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. *J Infect Dis*, 2005. 192(12): p. 2117-23.

50. Bernstein, D.I., et al., The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. *Vaccine*, 2010. 28(21): p. 3748-53.
51. Bernstein, D.I., et al., Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines. *Clin Vaccine Immunol*, 2009. 16(5): p. 699-705.
52. Sweeney, K.A., et al., A recombinant *Mycobacterium smegmatis* induces potent bactericidal immunity against *Mycobacterium tuberculosis*. *Nat Med*, 2011. 17(10): p. 1261-8.
53. Kohl, S., et al., Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. *J Infect Dis*, 2000. 181(1): p. 335-9.
54. John, M., et al., Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. *J Infect Dis*, 2005. 192(10): p. 1731-40.
55. Nugent, C.T., et al., Analysis of the cytolytic T-lymphocyte response to herpes simplex virus type 1 glycoprotein B during primary and secondary infection. *J Virol*, 1994. 68(11): p. 7644-8.
56. Mueller, S.N., et al., Characterization of two TCR transgenic mouse lines specific for herpes simplex virus. *Immunol Cell Biol*, 2002. 80(2): p. 156-63.
57. Wallace, M.E., et al., The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. *J Virol*, 1999. 73(9): p. 7619-26.
58. Milligan, G.N., et al., T-cell-mediated mechanisms involved in resolution of genital herpes simplex virus type 2 (HSV-2) infection of mice. *J Reprod Immunol*, 2004. 61(2): p. 115-27.
59. Wang, K., et al., A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only Vero cells expressing exogenous HVEM. *J Virol*, 2012. 86(23): p. 12891-902.
60. Barletta, R.G., et al., Identification of expression signals of the mycobacteriophages Bxb1, L1 and TM4 using the *Escherichia-Mycobacterium* shuttle plasmids pYUB75 and pYUB76 designed to create translational fusions to the lacZ gene. *J Gen Microbiol*, 1992. 138(1): p. 23-30.

61. Yamaguchi, S., et al., A method for producing transgenic cells using a multi-integrase system on a human artificial chromosome vector. *PLoS One*, 2011. 6(2): p. e17267.
62. Xu, Z., et al., Accuracy and efficiency define Bxb1 integrase as the best of fifteen candidate serine recombinases for the integration of DNA into the human genome. *BMC Biotechnol*, 2013. 13: p. 87.
63. Hill, A., et al., Herpes simplex virus turns off the TAP to evade host immunity. *Nature*, 1995. 375(6530): p. 411-5.
64. Shu, M., et al., Selective degradation of mRNAs by the HSV host shutoff RNase is regulated by the UL47 tegument protein. *Proc Natl Acad Sci U S A*, 2013. 110(18): p. E1669-75.
65. Umbach, J.L., et al., MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. *Nature*, 2008. 454(7205): p. 780-3.
66. Cheshenko, N., et al., Herpes simplex virus triggers activation of calcium-signaling pathways. *J Cell Biol*, 2003. 163(2): p. 283-93.
67. Cheshenko, N. and B.C. Herold, Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. *J Gen Virol*, 2002. 83(Pt 9): p. 2247-55.
68. Cheshenko, N., et al., Multiple receptor interactions trigger release of membrane and intracellular calcium stores critical for herpes simplex virus entry. *Mol Biol Cell*, 2007. 18(8): p. 3119-30.
69. Immergluck, L.C., et al., Viral and cellular requirements for entry of herpes simplex virus type 1 into primary neuronal cells. *J Gen Virol*, 1998. 79 (Pt 3): p. 549-59.
70. Nixon, B., et al., Genital Herpes Simplex Virus Type 2 Infection in Humanized HIV-Transgenic Mice Triggers HIV Shedding and Is Associated With Greater Neurological Disease. *J Infect Dis*, 2014. 209(4): p. 510-22.
71. Cheshenko, N., et al., HSV usurps eukaryotic initiation factor 3 subunit M for viral protein translation: novel prevention target. *PLoS One*, 2010. 5(7): p. e11829.
72. Carbonetti, S., et al., Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies. *PLoS One*, 2014. 9(1): p. e86905.
73. Janes, H., et al., Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. *J Infect Dis*, 2013. 208(8): p. 1231-9.

74. Ferre, A.L., et al., Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. *J Virol*, 2010. 84(19): p. 10354-65.
75. Schiffer JT, Corey L (2013) Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. *Nat Med* 19:280–90.
76. Sydiskis, Schultz (1965) Herpes simplex skin infection in mice. *J Infect Dis* 115:237–46.
77. Nixon B et al. (2013) Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. *J Virol* 87:6257–69.
78. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV (2005) FcγRIV: a novel FcR with distinct IgG subclass specificity. *Immunity* 23:41–51.
79. Wang K et al. (2015) A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. *J Virol* 90:562–74.
80. Boukhvalova M et al. (2015) Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat *Sigmodon hispidus* Model. *J Virol* 89:9825–40.
81. Yin H et al. (2013) IL-33 accelerates cutaneous wound healing involved in upregulation of alternatively activated macrophages. *Mol Immunol* 56:347–53.
82. Rak GD et al. (2015) IL-33-Dependent Group 2 Innate Lymphoid Cells Promote Cutaneous Wound Healing. *J Invest Dermatol*.
83. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. *Nature* 475:110–3.
84. Simmons, Nash (1984) Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease.
85. Ligas, Johnson (1988) A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells.
86. Nixon B et al. (2013) Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. *Journal of virology* 87:6257–69.

87. Ejercito, Kieff, Roizman (1968) Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. *J Gen Virology* 2:357–64.
88. Brown, Ritchie, Subak-Sharpe (1973) Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. *The Journal of general virology* 18:329–46.
89. Wan Y, Renner DW, Albert I, Szpara ML (2015) VirAmp: a galaxy-based viral genome assembly pipeline. *Gigascience* 4:19.
90. Larkin MA et al. (2007) Clustal W and Clustal X version 2.0. *Bioinformatics* 23:2947–8.
91. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S (2013) MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. *Mol Biol Evol* 30:2725–9.
92. Bologna-Molina R, Damián-Matsumura P, Molina-Frechero N (2011) An easy cell counting method for immunohistochemistry that does not use an image analysis program. *Histopathology* 59:801–3.
93. Ackerman M et al. (2011) A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. *Journal of Immunological Methods* 366:8–19.
94. Petro C et al. (2015) Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. *Elife* 4.
95. Cheshenko N et al. (2013) HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression. *FASEB J* 27:2584–99.
96. Kolb AW, Larsen IV, Cuellar JA, Brandt CR (2015) Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains. *J Virol* 89:6427–34.
97. Dudek TE, Torres-Lopez E, Crumpacker C, Knipe DM (2011) Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. *J Infect Dis* 203:1434–41.

What is claimed is:

1. A method of eliciting an immune response in a first subject against an HSV-2 and/or HSV-1 infection, comprising effectuating passive transfer to the first subject of an amount of a product from a pregnant female immunized with HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, wherein the product comprises antibodies induced thereby, effective to elicit an immune response against an HSV-2 and/or HSV-1 infection in the first subject, wherein the first subject is a fetus or neonate.
2. The method of Claim 1, wherein the product comprises serum of the pregnant female.
3. The method of Claim 1 or Claim 2, wherein the product comprises breast milk of the pregnant female.
4. The method of any one of Claims 1 to 3, wherein the first subject is a fetus.
5. The method of any one of Claims 1 to 4, wherein the first subject is a neonate.
7. The method of Claim 5, wherein the first subject is born from a second subject.
8. The method of Claim 4, wherein the pregnant female is pregnant with the fetus.
9. The method of any one of Claims 1 to 8, wherein the first subject and the pregnant female are human.
10. The method of any one of Claims 1 to 9, wherein the product comprises antibodies elicited by immunization of the pregnant female with the HSV-2 having the deletion.
11. The method of any one of Claims 1 to 10, wherein the method elicits an immune response in the first subject against an HSV-2.

12. The method of any one of Claims 1 to 11, wherein the method elicits an immune response in the first subject against an HSV-1.
13. The method of any one of Claims 1 to 12, wherein the product further comprises an immunological adjuvant.
14. The method of Claim 13, wherein the product further comprises an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D.
15. A method of inhibiting a perinatal HSV-1 and/or HSV-2 infection in a neonate comprising administering to a female pregnant with a fetus which will become the neonate an amount of an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, effective to inhibit a perinatal HSV-1 and/or HSV-2 infection in a neonate.
16. A method of inhibiting HSV-1 and/or HSV-2 viral dissemination from a mother to her neonate comprising administering to the mother an amount of an HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, effective to inhibit HSV-1 and/or HSV-2 viral dissemination from a mother to her neonate.
17. The method of Claim 16, wherein the mother is pregnant with a fetus which will become the neonate.

18. The method of Claim 15 or Claim 16, wherein the HSV-1 infection or HSV-1 viral dissemination is inhibited.
19. The method of Claim 15 or Claim 16, wherein the HSV-2 infection or HSV-2 viral dissemination is inhibited.
20. The method of Claim 1, wherein an immune response is elicited against HSV-1.
21. The method of Claim 1, wherein an immune response is elicited against HSV-2.
22. The method of Claim 1, Claim 15 or Claim 16, wherein the complementing cell is a VD60 cell.
23. The method of any one of Claims 1 to 22, wherein the pregnant female, the mother, or the second subject is seronegative for HSV-1, seronegative for HSV-2, or seronegative for both HSV-1 and HSV-2.
24. The method of any one of Claims 1 to 23, wherein the pregnant female or the mother is subcutaneously administered the HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof.
25. The method of Claim 24, wherein the pregnant female or the mother is administered a subcutaneous boost dose of the HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof after an initial subcutaneous administration of the HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene.






Fig. 1

A



B



C




Fig. 2A-C




Fig. 3A-C




Fig. 4A-C




Fig. 5A-F




Fig. 6A-C




Fig 7A-D




Fig. 8A-8C




Fig. 9A-9D




Fig. 11A-11D





Fig. 12A-12H




Fig. 13




Fig. 14A-14F

Fig. 15A-15C




Fig. 16A-16D




Fig. 18A-18D




Fig. 19A-19B




Fig. 20





Fig. 21A-21B

A



B





Fig. 22A-22D



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2020/012170

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/245 A61P17/00 A61P35/00 A61P25/00
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61K A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, Sequence Search, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHRISTOPHER PETRO: "Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease", ELIFE, vol. 4, 10 March 2015 (2015-03-10), pages 1-18, XP055682541, DOI: 10.7554/eLife.06054 abstract page 5, paragraph 1; figure 5	1-25
Y	YIKE JIANG ET AL: "ABSTRACT", MBIO, vol. 8, no. 4, 6 September 2017 (2017-09-06), XP055682542, DOI: 10.1128/mBio.00678-17 abstract	1-25

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 27 May 2020	Date of mailing of the international search report 03/06/2020
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Fleitmann, J
--	---

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2020/012170

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 2019/240321 A1 (HEROLD BETSY [US]) 8 August 2019 (2019-08-08) claims 1-25 -----	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2020/012170

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2019240321	A1	NONE	08-08-2019